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ABSTRACT 
 
P-cadherin is a cell-cell adhesion molecule, whose overexpression is associated with 
proliferative lesions of high histological grade, basal-like phenotype, decreased cell 
polarity and worse survival of breast cancer patients (1). Using in vitro models, it was 
showed that P-cadherin overexpression promotes invasive and migratory capacities (2, 3), 
as well as mediates cancer stem cell (CSC) activity (4). Nevertheless, little is known about 
CDH3/P-cadherin gene regulation in breast cancer. 
With this project, our long term goal was to disclose molecular mechanisms regulating P-
cadherin expression in breast cancer, as well as in normal epithelial tissues. Actually, we 
were able to show that CDH3 gene is a direct transcriptional target of CCAAT/enhancer-
binding protein  (C/EBP) and p63 transcription factors in breast cancer cells. 
 C/EBP is a transcription factor which share some of the mentioned features with P-
cadherin, such as its overexpression in aggressive and proliferative tumours, with poor 
differentiation, basal-like phenotype and association with worse prognosis of breast 
cancer patients (5, 6). In fact, we have previously demonstrated that C/EBP was able to 
up-regulate CDH3 promoter in breast cancer cells (7). In this study, we proved, by 
chromatin immunoprecipitation (ChIP) and site-directed mutagenesis, the direct link 
between C/EBP and CDH3/P-cadherin gene, as well as the co-localization of P-cadherin 
and C/EBP in the same tumour cells by immunohistochemistry. These results were 
corroborated by the increase of CDH3 promoter activity and P-cadherin expression in 
human breast cancer cells, in response to C/EBP isoforms. We also demonstrated the 
isolated and distinct inducer rates of C/EBP isoforms and their synergetic effect in CDH3 
promoter. 
P63 is also a transcription factor implicated in tumour formation and progression, with 
evidence for both tumour suppressive and oncogenic properties (8). Interestingly, Carrol 
et al. suggested that p63 plays an important role in the modulation of gene expression 
programs involved in cell adhesion (9) and, more recently, it was actually demonstrated 
that CDH3/P-cadherin gene is a transcriptional target of p63 in a human limb bud and hair 
follicle model (10). 
Herein, concerning p63 isoforms, we have observed their ability to differently modulate the 
activity of CDH3 promoter in breast cancer cells, being the truncated TAp63γ isoform the 
one which greater represses CDH3 activity. Additionally, we observed a decreased of the 
P-cadherin induced functional proprieties, such as invasion and mammosphere formation 
efficiency, when cells were transfected with TAp63γ. However, we proved that this effect 
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was dependent on the p53 wild type or mutated status. 
Overall, the results obtained under this project allowed us to understand the relationship 
between P-cadherin expression and the transcription factors C/EBP and p63, as well as 
their putative importance for the malignant phenotype of P-cadherin-overexpressing 
breast cancer cells. As ongoing and future work, we are trying to disclose if these 
mechanisms, or even new ones, regulating CDH3/P-cadherin expression in invasive 
carcinomas, are also important in the process of differentiation of normal epithelial tissues. 
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RESUMO 
 
A P-caderina é uma molécula de adesão célula-célula, cuja sobre-expressão em 
carcinomas da mama se associa com lesões mais proliferativas, de alto grau histológico, 
com fenótipo do tipo basal e com um pior prognóstico para as doentes (1). Utilizando 
modelos in vitro, demonstrou-se que a P-caderina, quando sobre-expressa em células de 
cancro da mama, promove invasão e migração celular (2, 3), regulando também a 
actividade das células neoplásicas com propriedades estaminais (ou cancer stem cells) 
(4). No entanto, pouco se sabe acerca dos mecanismos moleculares que regulam a sua 
expressão ao nível da actividade do gene que a codifica (gene CDH3). 
Com este projecto, tinhamos como principal objectivo identificar mecanismos moleculares 
importantes na regulação da expressão da P-caderina em cancro da mama, assim como 
em tecidos epiteliais normais. De facto, fomos capazes de demonstrar que o gene CDH3 
constitui um alvo directo dos factores de transcrição CCAAT/enhancer-binding protein  
(C/EBP) e p63 em células de cancro da mama. 
O factor de trancrição C/EBP partilha algumas das características de agressividade 
tumoral mencionadas para a P-caderina, uma vez que a sua sobre-expressão está 
também associada a tumores mais agressivos e proliferativos, pouco diferenciados, do 
sub-tipo basal e de pior prognóstico (5, 6). Neste trabalho pretendemos explorar a ligação 
entre C/EBP e o gene CDH3, uma vez que demonstrámos previamente que este 
promove a actividade do promotor desta caderina em células de cancro de mama (7). 
Com este intuito, recorremos a imunoprecipitação de cromatina (ChIP) e mutagénese 
dirigida para demonstrar a ligação da C/EBP ao promotor do gene CDH3. Por 
imunohistoquímica, vimos ainda a co-localização de C/EBPβ e P-caderina nas mesmas 
células tumorais. In vitro, observámos ainda um aumento da actividade do promotor 
CDH3, bem como dos níveis de P-caderina em resposta à transfecção das isoformas de 
C/EBPβ. 
A p63 é também um factor de transcrição, descrito como estando envolvido na formação 
e progressão tumoral, possuindo uma actividade tanto oncogénica como supressora 
tumoral (8). Curiosamente, Carrol et al. publicou que a p63 tem um papel importante na 
modulação de genes envolvidos em adesão celular (9) e, em modelos de 
desenvolvimento, o gene CDH3 foi descrito como alvo directo da p63 (10). Neste estudo, 
relativamente às diferentes isoformas de p63, observámos diferentes efeitos na 
actividade do promotor CDH3, sendo a isoforma TAp63γ a maior inibidora da actividade 
do promotor. De facto, quando transfectadas com TAp63γ, as células de cancro da mama 
apresentam um decréscimo de expressão de P-caderina, assim como consequente 
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diminuição das capacidades de invasão e formação de mamosferas, propriedades 
funcionais induzidas por esta caderina. No entanto, provámos ainda que este efeito é 
dependente do status da p53.  
Em conclusão, os resultados obtidos neste trabalho revelaram-se importantes para 
clarificar a relação entre a expressão de P-caderina e os factores de transcrição C/EBP 
e p63, assim como a importância destes na malignidade em carcinomas de mama com 
sobre-expressão de P-caderina. Neste momento, estamos a estudar se os mecanismos 
moleculares que regulam a expressão de P-caderina em carcinomas da mama são 
também importantes no processo de diferenciação de tecidos epiteliais normais. 
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1. EPITHELIAL CADHERINS 
 
The maintenance of adult tissue architecture mainly depends on the structural and 
functional integrity of cadherins, a superfamily of transmembrane glycoproteins that 
mediate calcium-dependent adhesion between neighbouring cells of all solid tissues of the 
organism. Cadherins have a crucial role in determining the epithelial phenotype, being 
involved in several processes such as cell polarity, cytoskeleton organization, 
differentiation and migration (11-14). 
The epithelial cadherins, CDH1/E-(epithelial) and CDH3/P-(placental) cadherins, as the 
name says, have epithelium-specific expression and are preferentially located at 
intercellular junctions of adherent type, sharing a common basic structure, but with 
different molecular weights, specificity binding and tissue distribution (13, 15). 
 
1.1. GENE STRUCTURE 
 
E- and P-cadherin genes have been mapped to 16q22.1, being CDH3 32 kb upstream of 
CDH1 (Figure I.1). Both display 16 exons and share a remarkable degree of conservation 
in intron positions, as well as a large intron after exon 2 (15). Additionally, both CDH1 and 
CDH3 genes harbour a 5′‐located CpG island in their promoters (16, 17). 
CDH1 transcription start site (TSS) is currently annotated at the coordinate 68,771,128 bp, 
the translation start site (ATG) 194 bp downstream of it (18) and its canonical promoter 
starts at least 125 bp upstream of the TSS and ends 27 bp downstream of it (19, 20). In 
this area there is no TATA box, but several regulatory elements such as GC boxes, E-
boxes and a CAAT box are present (19, 21). Moreover, it was found, less than 500 bp 
upstream from the canonical ATG, an Alu repeat (AluJo) which may uncover putative new 
molecular mechanisms of gene regulation. 
Concerning CDH3 gene, its TSS is currently annotated to the coordinate 68,678,739 bp 
on the forward strand and the ATG is found 553 bp downstream of the TSS. The CDH3 
promoter, similarly to CDH1, exhibits no TATA box, neither an homologous sequence to 
the palindromic sequence E-pal, but includes a CAAT box, two putative AP2-binding 
motifs and a GC-rich region containing putative Sp1-binding sites, all highly conserved. An 
AluJo repeat was described, as well as in CDH1, ~700 bp upstream of the ATG and 
putatively encloses gene regulation or exonisation features (20, 22). 
Interestingly, in the non-coding part of both CDH1 and CDH3 gene, it was described an 
intron, intron 2, with more than 63 Kb and 30 kb in length, respectively (23). This large 
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intron is a structurally conserved feature across mammals, which suggests the presence 
of common cis-regulatory elements, yet to be described. 
Ensembl database currently describes four and two transcripts arising from the CDH1 and 
CDH3 gene locus, respectively (23). 
Figure I.1. Structure of the human CDH3 and CDH1 genes. The CDH3 and CDH1 genes are located on 
chromosome 16q22.1 and exhibit a lot of structural similarities. Adapted from Paredes J, 2012 (24). 
 
1.2. PROTEIN STRUCTURE AND FUNCTION 
 
The epithelial-calcium dependent cell–cell adhesion is achieved by the establishment of 
mainly, but not exclusively, homophilic interactions between two cadherin molecules of 
adjacent cells to form a homodimer (25, 26). Epithelial cadherin mature proteins are 
organised in three major structural domains: a large extracellular domain, a single 
transmembrane domain and a short intracellular/cytoplasmic domain (27) (Figure I.2). 
The extracellular (EC) segment is composed by five tandemly repeated domains, known 
as cadherin motifs, which constitute a key element for their classification. These 
extracellular domains are sequences of 110 residues, commonly designated as EC1-EC5 
(15, 27, 28). From the five EC domains, four are characteristic cadherin repeats, where is 
observed the highly conserved histidine, alanine and valine (HAV) tripeptide within the 
most N-terminal extracellular repeat (EC1), which plays a key role in the interaction 
between cadherins and consequent adhesive properties (29). The role of the other 
cadherin repeats (EC2-5) in the cell-cell interaction remains a matter of debate. 
In the intercellular space, cadherin dimmers interact via their EC1 with cadherin dimers of 
the neighbouring cell, establishing a “zipper-like” structure at the level of the adherent 
junctions of epithelial cells. The correct conformation of cadherin molecules is stable only 
in presence of Ca2+, whose binding with the extracellular portion of the polypeptide chain 
is a prerequisite for cadherin mediated cell-cell adhesion. Calcium binding sites consist in 
short highly conserved amino acid sequences, which are located between neighbouring 
EC repeats (15, 30, 31). 
The intracellular domain of cadherins comprises about 150 aminoacid residues (29) and it 
is divided into a membrane proximal region, the juxtamembrane domain (JMD), and a 
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catenin-binding domain (CBD), which are known to be essential for cadherin function.  It 
has been shown that the strength of cadherin interactions relies on the formation of 
complexes with catenins (ctn), which serve to link the cadherin cytoplasmic tail to the actin 
cytoskeleton (30, 32). The JMD is directly connected with p120-catenin (p120ctn) (31, 33, 
34), while the cytoplasmic proteins, - or -catenins, bind in a mutual-exclusive manner to 
the CBD and to -catenin, which mediates interaction with the actin cytoskeleton (35-37). 
The interactions of cadherins with the actin cytoskeleton are of no importance in the first 
steps of intercellular interaction, but are extremely important for contact stabilization and 
maturation, which leads to increased strength in cell-cell adhesion (38). 
Interestingly, although the very similar aminoacid sequence between E-cadherin and P-
cadherin (about 71% similarity in the extracellular domain, and 89% in the entire 
cytoplasmic tail), these harbour distinct patterns of tissue expression, as well as different 
biological functions (24). 
 
Figure I.2. CDH3/P-cadherin gene, protein structure and organization. Cadherins are organized in three 
major structural domains: an extracellular domain composed by 5 cadherin repeats (EC), a transmembrane 
domain and an intracellular domain, which links with actin cytoskeleton through catenins, establishing the 
cadherin/catenin complex. Adapted from Albergaria A, 2011 (1). 
EC1 EC3 EC5 EC2 EC4 
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1.3. EXPRESSION IN NORMAL TISSUES 
 
Epithelial cadherins play important roles in maintaining the structural integrity of adult 
epithelial tissues and are mainly involved in cell differentiation, as well as in tissue and 
organ development during embryogenesis (21, 39). In fact, E- and P-cadherin are the first 
adhesion molecules that are expressed in the embryo, and its proper development is 
assured only under conditions of tightly regulated cell-cell and cell-matrix interactions (40). 
Therefore, the majority of adult epithelial tissues, such as epidermis, breast, uterine 
cervix, prostate and lung, express E- and P-cadherin (Figure I.3). However, their 
distribution differ along the tissues: E-cadherin is usually found in epithelial differentiated 
cell layers, while P-cadherin expression is restricted to undifferentiated and proliferative 
cells, which are usually found in the basal layers of epithelial tissues (39, 41, 42). 
The specific and well defined expression patterns of E- and P-cadherins within normal 
epithelial tissues (Figure I.3) suggest their distinct and complementary role in epithelial 
cell differentiation and development, where E-cadherin is essential to maintain the 
structural continuum of a differentiated epithelium (43, 44), which importance is clearly 
demonstrated by the lethality of E-cadherin KO-mice in early stages of embryogenesis 
(45); concerning P-cadherin, it seems to be necessary to restrain differentiation of 
proliferative cells of epithelial tissues and to wound regeneration (41), since P-cadherin-
mediated signals are crucial to maintain the undifferentiated state of an epithelium. In 
contrast to E-cadherin, P-cadherin KO-mice are viable, but virgin females display 
precocious differentiation of the mammary gland (46). 
Germline mutations of E-cadherin and P-cadherin are also significantly associated to 
human developmental defects. In the case of E-cadherin, germline mutations of its 
codifying gene lead to various aberrant transcripts, which have been associated to 
congenital midline malformations, namely for the craniofacial morphogenesis, such as lip 
and palate clefting (47). On the other hand, CDH3 germline mutations were shown to 
cause P-cadherin functional inactivation, leading to developmental defects associated with 
two inherited syndromes in humans: 1) hypotrichosis with juvenile macular dystrophy 
(HJMD) (48, 49) and 2) ectodermal dysplasia, ectrodactyly, and macular dystrophy (EEM 
syndrome) (50). Both diseases are characterized by sparse hair and macular dystrophy of 
the retina, while only EEM syndrome shows split hand/foot malformation (SHFM). 
Mammary development or other epithelial bud structures do not present defects; however, 
it is known that during bud patterning, a special arrangement occurs, where cells change 
their interaction with their neighbours and break their attachments to the extracellular 
matrix (ECM), by a specific activation of some transcriptional programs (10). 
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Figure I.3. E- and P-cadherin immunoexpression in normal epithelial tissues. E- and P-cadherin are co-
expressed in cells of normal epithelial tissues that constitute the proliferative and undifferentiated niche of 
epithelial tissues, whereas differentiated epithelial cells only express E-cadherin. 
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2. EPITHELIAL CADHERINS IN CANCER 
 
Loss of cell-cell adhesion is a hallmark of epithelial tumours, since it allows cells to detach 
from each other, resulting in the destruction of the histological architecture and, 
consequently, in cancer invasion (51). The majority of the studies implicating cadherins in 
carcinogenesis have been focused on E-cadherin, since it is the major cadherin 
expressed by epithelial cells. In 90% of all epithelial cancers, the turning point in cancer 
progression is mediated by E-cadherin dysfunction (52, 53). In vitro and in vivo studies 
showed that inhibition of E-cadherin function turned non-invasive epithelial and polarized 
cells into invasive cells, showing a role for this protein as an important suppressor of cell 
invasion. Indeed, decreased or loss of E-cadherin expression and/or function has already 
been described in most human carcinomas (26, 54), being associated to tumours with an 
increased infiltrative pattern of growth, including sporadic and hereditary diffuse gastric 
and lobular breast cancers (55, 56). 
Moreover, in tumours characterized by loose cell-cell adhesion, structural alterations 
(mutations and deletions) of CDH1 gene are found as initiating events (57-59), while 
epigenetic alterations (promoter methylation) or expression of E-cadherin repressors 
emerge as progression events in a wider range of advanced stage tumours (16, 60, 61). 
Furthermore, loss of E-cadherin has also been implicated in the induction of epithelial to 
mesenchymal transition (EMT), which frequently occurs during cancer invasion, and is 
considered the basis for the acquisition of metastatic capacity by cancer cells (62, 63). 
Despite the correlation between E-cadherin dysfunction and malignancy, E-cadherin is not 
lost in some epithelial tumours, being concomitantly co-expressed with other cadherin, like 
P-cadherin (64). Indeed, some studies have shown that the expression of an inappropriate 
cadherin in epithelial cells is another way to alter cell endogenous cadherin function (65-
67). Mesenchymal cadherins, for example, like N- or R-cadherin (44, 68), can have a 
direct and dominant influence on the phenotype of epithelial cells, despite their continued 
expression of E-cadherin (69). Our group also showed that patients with invasive breast 
carcinomas co-expressing both E- and P-cadherin have as poor prognosis as those with 
carcinomas lacking both E- and P-cadherin, which suggests that P-cadherin could be a 
modulator of E-cadherin function in cancer cells that do not harbour structural E-cadherin 
gene alterations (64, 70). 
In fact, the role played by P-cadherin in carcinogenesis is still a matter of debate. 
However, aberrant expression of P-cadherin has been described in several solid tumours 
such as breast (22, 42, 71, 72), gastric (73), endometrial (74), ovarian (75), prostate (76, 
77), pancreatic, colorectal, and bladder carcinomas (78), as well as in basocellular and 
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squamous carcinomas of the skin (79). In all these tumours, P-cadherin was preferentially 
expressed in invasive rather than in in situ lesions, showing that its aberrant expression 
could be a useful marker of invasion capacity of tumour cells, as well as a general marker 
of poorly differentiated tumours with aggressive clinical behaviour and a novel tumour-
associated antigen (78). More specifically, increased P-cadherin expression is a poor 
prognosis factor for breast cancer patients, being presently mainly in triple-negative basal-
like tumours (ER, PgR and HER-2 negative), which still lack an efficient targeted therapy. 
 
2.1. P-CADHERIN IN BREAST CANCER 
 
The role of E-cadherin in breast carcinogenesis has been extensively studied and results 
suggested a correlation between its loss or reduced expression and cancer progression 
(16, 51, 80). In contrast, overexpression of P-cadherin has been associated to 
carcinogenesis, increased tumour cell motility, migration, invasion and metastasis (42, 81) 
in this cancer model. 
P-cadherin is de novo expressed in 20% to 40% of invasive breast carcinomas, as well as 
in 25% of ductal carcinomas in situ (DCIS), being reported as a marker of poor prognosis 
in breast cancer. In fact, P-cadherin-positive carcinomas are significantly associated with 
short-term overall survival, as well as with distant and loco-regional relapse-free interval 
(22, 72, 82, 83), being considered a valuable prognostic factor. Overexpression of P-
cadherin has also been associated with high histological grade tumours, as well as with 
well-established markers and biological parameters of poor prognosis, like the expression 
of Ki-67, epidermal growth factor receptor (EGFR), cytokeratin 5 (CK5), vimentin, p53, 
and HER-2, high proliferation rates (MIB-1) and mitotic index and decreased cell 
differentiation (22, 72, 82, 84). P-cadherin expression is also inversely related with age at 
diagnosis, hormonal receptors (ER and PgR), and Bcl-2 expression (22, 72, 82, 83). 
Besides these strong associations, transgenic mice overexpressing CDH3/P-cadherin in 
the luminal epithelial layer of the mammary gland showed normal morphogenesis, 
architecture, lactation and involution, with no spontaneous formation of mammary tumours 
(46). Nevertheless, it was demonstrated a significant increased shedding of soluble P-
cadherin in nipple aspirate fluids from women with breast cancer when compared with 
healthy subjects or with women with pre-cancer conditions, suggesting its possible release 
via a proteolytic processing in cancer cells (85). 
According with this, we have showed that one of the mechanisms underlying the 
increased invasive capacity of P-cadherin-overexpressing breast cancer cells is mediated 
by the secretion of MMPs (or metalloproteases), which are able to degrade the 
extracellular matrix (ECM) during invasion (2, 3); in addition, these proteases also cleave 
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P-cadherin extracellular domain, producing the soluble P-cadherin fragment, which needs 
to be inhibited to block cell invasion (3). Interestingly, this invasive phenotype mediated by 
P-cadherin was seemingly dependent on the concomitant expression of wild-type E-
cadherin: in cell models where P-cadherin showed an invasion promoter function, E-
cadherin was also expressed (2, 81, 86, 87); contrarily, in models expressing only P-
cadherin, this protein was described as an invasion suppressor (88-90). This dual 
functional role of P-cadherin was recently clarified, since we have been able to show that 
P-cadherin expression disrupts the normal invasive suppressor function of E-cadherin (70) 
by the destabilization of the normal cadherin/catenin complex (64); in fact, once in the 
cytoplasm, p120ctn can inhibit RhoA and activate other Rho GTPases, Rac1 and Cdc42, 
altering the actin cytoskeleton polymerization and promoting cell migration and motility, as 
well as an increased invasive and tumourigenic potential (70, 81). These results highlight 
the dual role of P-cadherin, either as an adhesion molecule, when expressed alone, or as 
an invasion promoter and poor prognosis marker when co-expressed with E-cadherin, 
reinforcing the importance of P-cadherin as a prognostic factor in breast cancer and 
suggesting that its overexpression is an alternative mechanism for cancer progression 
and invasion in E-cadherin-positive breast carcinomas. Therapeutically, this knowledge 
supports the development of anti-P-cadherin strategies to control highly aggressive breast 
carcinomas co-expressing both cadherins.  
Another clinical challenge in breast cancer research is to fight against resistance to 
current therapies, leading to recurrence and metastasis, features associated with cancer 
stem cells (CSC). CSCs have inherent ability to form a hierarchy, survive as circulating 
tumour cells and to form micrometastasis, remaining quiescent in distant sites for a long 
period. CSCs are also able to proliferate, originating more stem-like cells, which exhibit 
resistance to current therapies (91-94). Targeting CSCs, in combination with current 
therapies, is the forthcoming goal in cancer treatment. Interestingly, P-cadherin has a 
crucial role in mediating cancer stem cell (CSC) activity in breast cancer, since P-cadherin 
enriched populations were also enriched for anchorage independent survival 
(mammosphere forming efficiency, MFE), as well as for the expression of CD24, CD44, 
CD49f and ALDEFLUORbright, already described as CSC markers. P-cadherin also 
conferred resistance to X-ray induced DNA damage, supporting a role for this molecule in 
the maintenance of another CSC property (4). Hence, the strategy of directing therapies to 
the breast CSCs, by specifically targeting P-cadherin, could potentially help to eradicate 
CSCs. 
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2.2. P-CADHERIN AND SIGNALLING PATHWAYS 
 
Cadherins role in carcinogenesis and tumour progression seems not to lie only on their 
adhesive function, but also depends on their interaction with other molecules, such as 
cytoskeletal components, integrins, growth-factor receptors, and signalling pathways (61). 
This signalling-structural network is evident in the stabilization of the cadherin/catenin 
complex as a regulatory mechanism for oncogenic signalling pathways, which guide cell 
fate decisions through the modulation of specific genes at the transcriptional level and 
consequent regulation of several crucial cellular processes as proliferation, survival, 
polarization, differentiation, shape and migration (Figure I.4). 
Although E-cadherin-induced signalling pathways have been extensively studied in 
cancer, little is known about the signalling pathways activated by P-cadherin. As a 
cadherin and cell-cell adhesion molecule, P-cadherin is expected to share common 
signalling pathways with other cadherins; however, by microarray gene expression 
profiling of a breast cancer cell line (MDA-MB-231, negative for E- and P-cadherins) 
transfected with E- and P-cadherin, it has been revealed that both cadherins share 
common signalling pathways but 40 genes belonging to a wide range of biological 
functions were differentially modified by the expression of either cadherin type. These 
differentially modified pathways include signal transduction and growth factors (VEGFC, 
FGFR4), cell cycle (CCNA2), cell adhesion and ECM (CDH4, COL12A1), or cytokines and 
inflammation (IL24), among others (89). 
One of the molecules that has been several times referred has having a specific role in 
signalling related to P-cadherin is p120ctn. In fact, our group described the association 
between breast carcinomas co-expressing E- and P-cadherin, p120ctn cytoplasmic 
localization and poor patient survival (64), due to P-cadherin’s interference in normal 
binding of p120ctn to E-cadherin (70). Indeed, transfection of HEK293T cells with several 
mutants of P-cadherin showed that only the ones with altered JMD were not able to 
induce cell invasion in in vitro cell models, which showed that the pro-invasive activity of 
P-cadherin requires the JMD of its cytoplasmic tail (2). Moreover, it was described that 
induced cell migration by P-cadherin expression was due to activation of Rho GTPases, 
Rac1 and Cdc42, through the accumulation of p120ctn in the cytoplasm (81). In 
pancreatic and ovarian cancer cell models, it was also reported that p120ctn signalling 
mediated by P-cadherin expression also lead to increased activity levels of Rac1 and 
Cdc42 (81, 87). This connection between cadherins and Rho GTPases is made by 
p120ctn and highlight the role of P-cadherin and the assembly of the adhesion complex in 
the organization of the cytoskeleton, with great consequences on cell behaviour (95-98). 
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Furthermore, p120ctn pathway has been also shown to intermediate P-cadherin 
cooperation with insulin-like growth factor-1 receptor promoting metastatic signalling of 
gonadotropin-releasing hormone in ovarian cancer (87). Another study has shown that 
p120ctn and P-cadherin, but not E-cadherin, regulate cell motility and invasion of DU145 
prostate cancer cells (99). 
P-cadherin regulatory role in cell migration was also related with the expression of the 
non-muscle myosin II-B isoform, an ATP-dependent molecular motor protein that can 
interact with and contract filamentous actin (F-actin) (100), another evidence of the 
coordinated cross-talk between adhesion molecules and cellular migration-related 
proteins. In addition, the role of P-cadherin in breast cancer cell invasion were clarified 
when we found that the presence of P-cadherin, in an E-cadherin positive cellular 
background, is able to provoke the secretion of pro-invasive factors, such as MMP-1 and 
MMP-2, leading to P-cadherin ectodomain cleavage (sP-cad) which induces a pro-
invasive activity by itself (3). 
Figure I.4. Signalling pathways regulated by P-cadherin expression. P-cadherin signals are transduced 
by many intracellular signalling pathways, which ultimately result in alterations of the cancer cells survival, as 
well as cell migration and invasion capacity. Adapted from Albergaria A, 2011 (1). 
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In an oral squamous cancer cell model, which is deficient for classical cadherins, the 
induced-P-cadherin overexpression led to a gain of an epithelial-like morphology, with 
Snail translocation to the cytoplasm. It has been described that glycogen-synthase-
kinase-3 (GSK-3) bound to Snail, as well as that an increase in activated GSK-3 
phosphorylates Snail, leading to its cytoplasmic translocation (88). In the same model, it 
was also showed that Slit-2, a secreted ECM glycoprotein that acts as a molecular 
guidance signal in cellular migration, facilitates the interaction of P-cadherin with Robo-3, 
its receptor, inhibiting cell migration (101). 
Another signalling pathway that is known to affect both gene expression and cell migration 
is the Wnt signalling pathway, a powerful regulator of cell proliferation and differentiation. 
In fact, β-catenin, a central player in Wnt signalling, is directly involved in both gene 
transcription and cell adhesion due to its transcriptional activation of CDH3/P-cadherin 
and by also being one of the players that constitute cadherin-catenin complexes (102, 
103). Whenever β-catenin is not bound to cadherins and is free in the cytoplasm, it is 
rapidly phosphorylated and degraded by ubiquitin-proteosome pathway (102, 104). 
Finally, it is important to highlight that the effect of cadherins on the overall gene 
expression program of cancer cells is highly dependent on the cellular type and the 
biological context. 
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3. CDH3/P-CADHERIN GENE REGULATION 
 
Regulation of cadherin-mediated adhesion seems to be a very dynamic, elegant and 
complex net of mechanisms and players, which underlie the dynamics of the adhesive 
interaction between cells. Although the described evidences that the expression of 
inappropriate cadherins can result from growth factors and hormones stimulation in the 
tumour microenvironment or from changes in the promoter regions of cadherins and 
transcriptional and post-translational regulation, specific data concerning CDH3 gene 
regulation is still very limited. 
 
3.1. EPIGENETIC MODULATION OF P-CADHERIN EXPRESSION 
 
Epigenetic alterations, resulting in the loss of tumour suppression genes, are frequently 
involved in tumour development and progression. Moreover, aberrant DNA methylation or 
acetylation in tumour cells have been described as a trigger of improper cadherin 
expression, which is a well-established mechanism of E-cadherin loss of expression (12). 
Concerning CDH3 gene, P-cadherin negative epithelial/luminal normal breast cells are 
consistently methylated in a specific region of the CDH3 gene promoter, whereas in 
breast cancer, it was established the existence of a significant correlation between P-
cadherin overexpression and hypomethylation of this same specific promoter region (22). 
The important regulatory role of DNA methylation in the expression of this protein is also 
evident in other cancer models. Analyzing the CDH3 promoter revealed that it was 
hypomethylated in colonic aberrant crypt foci, in colorectal cancer and, occasionally, in the 
normal epithelium adjacent to cancer, inducing P-cadherin expression; however, in 
pancreatic and melanoma cancer models, CDH3 gene was shown to be silenced by 
aberrant methylation (105-107). Furthermore, demethylation of the CDH3 gene was found 
in 69% of primary gastric carcinomas and was significantly associated with increased 
TNM stage, implying that the aberrant demethylation of CDH3 is a frequent event in 
gastric carcinomas, (108). 
Interestingly, not only methylation, but also other epigenetic events may regulate the 
CDH3 gene promoter. Such claim is sustained by its genomic structure, like the 
enrichment in CpG islands, as well as the attributed DNA hypersensitive sites. In fact, an 
up-regulation of CDH3 promoter activity and P-cadherin expression was observed by our 
group in cells treated with the histone deacetylases (HDAC) inhibitor Trichostatin A (TSA), 
showing that chromatin-activating modifications play an important role in the modulation of 
this gene (7). 
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3.2. CDH3 TRANSCRIPTIONAL REGULATION 
 
The pivotal molecular mechanism involved in CDH3/P-cadherin deregulation is mainly 
occurring at the promoter region of the gene and not by structural alterations of its coding 
sequences. An example of it is the regulation of P-cadherin expression by transcriptional 
factors: ERα (2), BRCA1 and c-Myc (109) as repressors and β-catenin (110), C/EBPβ (7) 
and p63 (10) as activators (Figure I.5). 
Figure I.5. Described transcriptional regulators of CDH3/P-cadherin promoter gene. It has been shown 
that β-catenin, p63 and C/EBP are transcriptional activators of CDH3 promoter, inducing its expression at the 
mRNA and protein level. In contrast, estrogen receptor (ER) and BRCA1/c-Myc/Sp1 complex act as 
transcriptional repressors of CDH3 promoter gene. Adapted from Albergaria A, 2011 (1). 
 
Since P-cadherin overexpressed breast tumours were essentially ER (estrogen receptor) 
negative, our group explored the link between ER signalling and the regulation of P-
cadherin expression in breast cancer. In 2004, it was described that the lack of ER 
signalling is responsible for the P-cadherin de novo expression, categorizing CDH3 as a 
putative oestrogen-repressed gene. In fact, it was also showed that the anti-oestrogen ICI 
182,780 is able to increase CDH3 promoter activity, mRNA and protein levels in a time 
and dose dependent manner (2). Furthermore, this anti-ER drug induces a chromatin 
structural remodelling, eventually allowing the binding of nearby transcriptions factors (7). 
In fact, upon endocrine therapy resistance and disease progression, there’s usually an 
acquired increased invasive phenotype of ER-positive breast cancer cells that may be due 
to this genomic de-repression effect. 
The expression profiling of BRCA1-deficient hereditary tumours has identified a pattern of 
gene expression similar to basal-like breast tumours (111, 112). Thus, as a gene 
associated with the basal-like phenotype in breast cancer, the mRNA and protein levels of 
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CDH3/P-cadherin gene were shown to be also transcriptionally repressed by functional 
BRCA1 protein in breast cancer cell lines. This repression is achieved after the formation 
of BRCA1 and c-Myc repressor complex (BRCA1-c-Myc complex) on the promoters of 
specific basal genes, including CDH3 gene, and represent a potential mechanism to 
explain the observed overexpression of key basal markers in BRCA1-deficient tumours 
(109). Actually, in breast carcinomas, it has been shown that P-cadherin expression is 
strongly associated with the presence of BRCA1 mutations (113), which means that this 
repression does not occur in breast cancer cells with a BRCA1 mutation and CDH3 gene 
is codified and expressed. 
Conversely, in vitro and in vivo studies also have shown that -catenin activates CDH3 
promoter leading to overexpression of P-cadherin in basal mammary epithelial cells. In 
fact, it was shown that activation of β-catenin signalling correlates with up-regulation of 
CDH3 promoter and P-cadherin expression, as well as downregulation of endogenous β-
catenin levels inhibited CDH3 promoter activity (110). 
Another putative transcription factor of P-cadherin is CCAAT/enhancer-binding protein  
(C/EBP), which was demonstrated as able to up-regulate CDH3 promoter in breast 
cancer cells. Moreover, the expression of P-cadherin and C/EBP are highly associated in 
human breast carcinomas and both linked with a worse prognosis of breast cancer 
patients (7). 
Carroll and collaborators demonstrated the importance of a classical transcription factor in 
the regulation of cell adhesion programmes in epithelial cells. This study showed that a 
p53 family related factor, p63, is a key regulator of adhesion and survival in basal cells of 
the mammary gland, showing that several cell adhesion-associated genes were 
downregulated due to p63 expression, which also led to detachment between mammary 
epithelial cells (9). This involvement of p63 in cell adhesion mechanisms was finally linked 
with CDH3 gene in developmental models, where P-cadherin has been described as a 
direct p63 transcriptional target, interplaying a crucial role in human limb bud and hair 
follicle development (10). 
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AIMS 
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Based on evidences that: 
1. P-cadherin is expressed in a specific niche of epithelial tissues, undifferentiated 
and proliferative cells, but overexpressed in 20 to 40% of the invasive breast 
carcinomas; 
2. P-cadherin overexpression is associated with malignancy, poor patient prognosis 
and tumour aggressive behaviour. 
 
Our main aim is to reveal the molecular mechanisms regulating P-cadherin 
expression in breast cancer, as well as in normal epithelial tissues. In order to 
achieve this goal, the following specific topics were addressed: 
 
1. To validate two putative CDH3/P-cadherin transcriptional regulators and to clarify 
their relationship with P-cadherin expression, malignant phenotype and more 
proliferative and aggressive breast cancer. 
1.1. C/EBPβ (Described in Chapter III) 
1.2. p63 (Described in Chapter IV) 
 
2. To disclose new mechanisms that regulate CDH3/P-cadherin expression in 
invasive carcinomas and evaluate if the same mechanisms are also important in 
the process of differentiation of normal epithelial tissues (Described in Chapter VI). 
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CHAPTER III 
C/EBPβ ISOFORMS AS TRANSCRIPTIONAL 
REGULATORS OF CDH3/P-CADHERIN GENE 
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Introduction
The molecular changes that occur during breast cancer
progression, which include the amplification/overexpression of
transcription factors, can disrupt the delicate balance between cell
proliferation, differentiation and apoptosis. C/EBPb is one of
those transcription factors, which has been implicated in cell cycle
regulation, playing an important role in mammary gland
development and oncogene-induced breast tumorigenesis [1–4].
Encoded by an intronless gene, C/EBPb is expressed as distinct
protein isoforms, which can accomplish distinct biological and
regulatory functions, ultimately leading to gene transactivation [5].
The longer C/EBPb proteins (liver-enriched transcriptional
activating proteins, LAP1 and LAP2) regulate proliferation and
differentiation of many cell types [6]; the shorter protein product
(liver-enriched transcriptional inhibitory protein, LIP) lacks the
transactivation domain and acts mainly as a dominant-negative
[7]. AS LAP isoforms, LIP also binds to the consensus sequences
within genomic DNA, sometimes even with a higher affinity than
the other C/EBPb isoforms [6,7]. In fact, LIP inhibits the
transcriptional activity of LAPs by competing for the same
consensus binding sites or by forming inactive heterodimers with
them. However, some emerging evidence suggest that LIP can also
act as a transcriptional activator in some cellular contexts [5].
In breast, C/EBPb most likely contributes to tumorigenesis
through significant elevations in the LIP:LAP ratio, mostly
observed in ER-negative, highly proliferative and metastatic
mammary tumours, usually associated with a poor patient
prognosis [8]. Indeed, LIP isoform overexpression has been
associated to a lack of contact inhibition, resulting in proliferation
and foci formation in epithelial breast cancer cell lines [9]. It has
been hypothesized that aberrant expression of C/EBPb-LIP
isoform may contribute to an increased growth rate and result in
a more proliferative and aggressive breast carcinoma.
P-cadherin, a classical cadherin encoded by the CDH3 gene
[10], has been explored by our group for several years and has
been also extensively associated with breast tumour aggressiveness.
This protein was found to be aberrantly expressed in 20–40% of
invasive ductal carcinomas, being strongly associated with
proliferative lesions of high histological grade, decreased cell
PLOS ONE | www.plosone.org 1 February 2013 | Volume 8 | Issue 2 | e55749
polarity and poor patient survival [11–16]. At the in vitro level, we
demonstrated that P-cadherin overexpression induces invasion
[14], motility and migration of wild-type E-cadherin expressing
breast cancer cells, through the secretion of pro-invasive factors,
such as matrix metalloproteinase (MMP)-1 and MMP-2 [17]. In
fact, P-cadherin-associated functions in breast cancer have been
widely studied, which reflects the growing importance of this
cadherin in human breast cancer biology and prognosis.
However, the mechanisms controlling its overexpression in
breast cancer have only recently started to be unrevealed [11,18].
In non-cancer models, CDH3 promoter was shown to be
genetically regulated through direct binding of transcription
factors, such as p63 [19] and b-catenin [20]. Gorski and
collaborators also demonstrated that BRCA1 and c-Myc form a
repressor complex on CDH3 promoter and on other promoters of
specific basal genes, representing a potential mechanism to explain
the overexpression of key basal markers in BRCA1-deficient breast
tumours [21]. Additionally, we established a direct link between P-
cadherin overexpression and the lack of oestrogen receptor (ER)-
signalling in breast cancer cells, categorizing CDH3 as a putative
ER-repressed gene [14]. In 2010, we described a regulatory
mechanism whereby a selective ER-downregulator is able to up-
regulate P-cadherin expression in MCF-7/AZ breast cancer cells
through chromatin remodelling at CDH3 promoter level [18]. This
epigenetic process was accomplished by the induction of high
levels of the active chromatin mark H3K4me2 and a consequent
de-repression of the CDH3 promoter, which exposed a high
number of putative C/EBPb transcription binding sites [18]. The
induction of CDH3 promoter activity by C/EBPb was also
confirmed by reporter assays, as well as its expression association
with worse prognosis of breast cancer patients [18].
However, since the mechanistic link and the consequent
transcriptional regulatory relevance of C/EBPb proteins on
CDH3 gene were not demonstrated, in the present study we
revealed that C/EBPb isoforms are indeed transcriptional
regulators of P-cadherin, directly interacting with conserved and
specific regions of the CDH3 promoter. Interestingly, we show that
this transcriptional activation is reflected in the P-cadherin protein
levels, especially for the LIP isoform. We conclude that CDH3 is a
newly defined transcriptional target gene of C/EBPb in breast
cancer.
Materials and Methods
Antibodies
The following primary anti-human antibodies were used for
Western Blot and/or Immunohistochemistry against: P-cadherin
(BD Transduction Biosciences, Lexington, KY), C/EBPb (Santa
Cruz Biotechnology, CA), b-actin (Santa Cruz Biotechnology) and
b-tubulin (Sigma-Aldrich, St. Louis, NO). Technical conditions
are described in Table S1 (Supporting Information). Anti-mouse
and anti-goat horseradish peroxidase-conjugated secondary anti-
bodies were used for WB [HRP-conjugated, dilutions: 1:2000]
(Santa Cruz Biotechnology). For chromatin immnunoprecipitation
(ChIP) assays, the following antibodies were used: anti-C/EBPb
(C-19, Santa Cruz Biotechnology), and two control IgGs (Active
Motif, CA and Santa Cruz Biotechnology).
Promoter Vectors and cDNA Constructs
The pLENTI-C/EBPb expression vectors (C/EBPb-LAP1, C/
EBPb-LAP2 and C/EBPb-LIP) were generated according to the
human CEBPB nucleotide sequence obtained from Ensembl and
Pubmed databases. Oligonucleotide primer sequences for LAP1,
LAP2, and LIP isoforms are listed in Table S2 (see Supporting
Information).
CEBPB cDNA was obtained from total RNA extracted from the
gastric cancer cell line AGS, and amplified for each CEBPB
isoform using HotStart Taq DNA Polymerase (Qiagen, Cam-
bridge, MA). Amplification was performed for 35 cycles as follows:
denaturation at 95uC for 1 minute, annealing at 60uC for LAP1
and LAP2 and 58uC for LIP for 1 minute, and extension at 68uC
for 2 minutes per cycle. PCR products for each isoform were
separated by electrophoresis in a 1.5% agarose gel and bands were
sequenced using the ABI Prism Dye Terminator Cycle Sequencing
Kit (Perkin-Elmer, Beaconsfield, UK). To validate the isoforms
nucleotide sequence, amplified products were purified through
Sepharose (GE Healthcare, Waukesha, WI) and sequenced on
both strands on an ABI Prism 3100 automated sequencer (Perkin-
Elmer). PCR products were inserted into the mammalian
expression vector pLENTI6/V5 Directional (Invitrogen, Ltd,
Paisley, UK), using manufacturer instructions, and incorporated
into chemically competent TOP10 E. coli (Invitrogen). Trans-
formed bacteria were grown overnight in ampicillin-supplemented
LB-Agar (Applichem, Germany). Plasmid DNA from transformed
E. coli cells was sequenced to check the orientation and nucleotide
sequence for each CEBPB isoform.
The human full-length CDH3-luciferase vector was generated
by our group, as previously described [18]. Normalization pRL-
CMV Renilla Luciferase Control Reporter Vector was purchased
to Promega (Promega Corporation, Madison, WI).
Immunohistochemistry
Double immunostaining for C/EBPb and P-cadherin was
performed in 3 mm sections of 23 formalin-fixed paraffin-
embedded (FFPE) invasive breast carcinomas that have previously
showed strong expression of both proteins, in order to illustrate
their consistent cellular co-localization. Standard immunohisto-
chemistry was performed as previously described [16]. For the
reaction, we used the Envision G2 Double-stain (DakoCytoma-
tion, Glostrup, Denmark), according to manufacturer instructions.
Specific conditions used for C/EBPb and P-cadherin are listed in
Table S1. FFPE sections from normal breast gland, skin or normal
gastric mucosa were used as positive controls for C/EBPb and P-
cadherin. Negative controls were performed by replacing the
primary antibody with PBS/non-immune serum.
The present study was conducted under the national regulative
law for the usage of biological specimens from tumour banks,
where the samples are exclusively available for research purposes
in the case of retrospective studies (National Regulative Law
number 12/2005 – I Serie-A, nu. 18–26th January, 2005).
Cell Culture
Human breast cancer cell line MCF-7/AZ was kindly provided
by Prof. Marc Mareel (Ghent University, Belgium) [22], while BT-
20 cells were purchased to American Type Culture Collection
(ATCC, Manassas, VA). Cell lines were routinely maintained at
37uC, 5% CO2, in the following media (Invitrogen): 50%
DMEM/50% HamF12 (MCF-7/AZ), or only DMEM (BT-20).
All media contained 10% of heat-inactivated foetal bovine serum
(Greiner Bio-one, Wemmel, Belgium), 100 IU/mL penicillin and
100 mg/mL streptomycin (Invitrogen).
Transient Transfection
For gene reporter assays, cells were grown in 96-well plates to
60–70% confluence and transfection was done using the liposome-
mediated FuGENE 6 transfection reagent (Roche Diagnostic
GmbH, Mannheim, Germany), prepared according to the
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manufacturer’s instructions. A ratio of FuGENE/DNA of 3:1 was
used. For protein expression assays, cells were grown in 6-well
plates to 60% confluence. Transient transfections of C/EBPb
expression vectors were done using Lipofectamine 2000 (Invitro-
gen), with a ratio of Lipofectamine/DNA of 3:1 and prepared
according to the manufacturer’s instructions.
For knock-down assays, cells were transiently transfected at 60%
confluence with specific siRNA for C/EBPb (100 nM, FlexiTube
siRNA – Hs_C/EBPb 5-Qiagen) using Lipofectamine 2000
(Invitrogen), according to the manufacturer’s procedure. Maxi-
mum C/EBPb knock-down was achieved after 48 h of incubation.
A siRNA with no homology to any gene was also used as a
negative control.
CDH3-luciferase Reporter Gene Analysis
Cells were co-transfected with pGL3-CDH3/luc promoter
vector (20 ng) and with pRL-CMV Renilla vector (5 ng). For
promoter analysis, 24 hours after transfection, cells were washed
twice in PBS-cold and lysed for firefly/Renilla luciferase assays,
using the Luclite Reporter Gene Assay System (Perkin Elmer),
according to the manufacturer. Luciferase bioluminescence from
Renilla was measured using native coelenterazine substrate
reagent (Lux Biotechnology, Edinburgh, UK). Individual trans-
fection experiments were repeated at least three times and in
quadruplicate per transfection condition. Empty pGL3-basic
vector and pGL3/luc-Control (pLUC) vector (Promega) were
included as controls in all CDH3-reporter assays. Luminescence
was read using the Wallac/Perkin Elmer-1450-028 Trilux
Microbeta (Perkin Elmer) plate reader, and the results are shown
as a mean of relative light units (RLU), which was calculated by
the ratio between the luminescence signal emitted from luciferase
and the luminescence signal obtained by the Renilla (normaliza-
tion).
Western Blot
Cells were lysed and the concentration of total protein was
determined by Bradford quantification. Western Blot was
performed as earlier described [17,18]. For MCF-7/AZ cell line,
due to its lower expression of P-cadherin, 50 mg of total protein
lysate has been loaded; for BT-20, due to its P-cadherin
overexpression, the gel loading was done only with 20 mg of
protein lysate. Membranes were incubated with primary antibod-
ies according to the conditions described in Table S1.
Site-Directed Mutagenesis
All the C/EBPb binding sites mutations in CDH3 promoter
were performed in order to impair the binding of any predicted
transcription factor: bioinformatic prediction tools were used to
blast all point mutated sequences. To introduce point mutations in
the CDH3 promoter region, the QuickChange Site-directed
Mutagenesis Protocol (Stratagene, Cedar Creek, USA) was
followed, and the oligos used are listed in Table S2. The PCR
cycles were set as follows: 95uC for 30 seconds; 16 cycles of 95uC
for 30 seconds, 55uC for 1 minute, and 68uC for 5 minutes.
Following PCR reaction, products were incubated with DpnI
(1 hour at 37uC) and transformed into E-coli competent cells
(Stratagene). All mutated plasmids were checked by sequencing
and primer sequences are also listed in Table S2.
Chromatin Immunoprecipitation (ChIP) Assay
For chromatin immunoprecipitation of the endogenous CDH3
promoter regions in MCF-7/AZ cells, the ChIP-ITTM kit (Active
Motif) was used and the assay was performed according with the
manufacturer’s procedures. Briefly, cells (4.56107) were fixed with
1% formaldehyde in culture medium for 10 minutes. Fixation was
stopped by incubating the cells for 5 minutes with a 16Glycine
Stop-Fix Solution, homogenized and centrifuged. The cell-pellets
were resuspended in a shearing buffer and sonicated into
chromatin fragments of 200–1500 bp in length. To reduce non-
specific background, sonication-sheared lysates were pre-cleared
with Protein G beads. The sheared chromatin lysates were
incubated with 5 mg of C/EBPb antibody or with a control rabbit
IgG, overnight at 4uC, and immunoprecipitated with Protein G
beads (2 hours at 4uC). The precipitated DNA-protein complex
was washed 7 times, eluted, incubated for 8 hours at 65uC in a
reverse cross-link buffer, and digested with proteinase K for
2 hours at 42uC. The resultant DNA was purified, resuspended in
DEPC H2O and quantified by real-time qPCR amplification. The
PCR primers sequences used in this amplification are listed in
Table S2.
For chromatin Immunoprecipitation in BT-20 cells and in an
invasive breast carcinoma highly positive for P-cadherin and C/
EBPb, the Magna ChIP G Kit (Millipore) was used, according to
manufacturer’s protocol. Basically, the essential steps applied for
BT-20 cells were the same as the ones used for MCF-7/AZ cells,
differing only in the use of protein G magnetic beads instead of
non-magnetic beads for simplicity of use. However, for the tumour
sample, some alterations in the basic protocol were employed.
Briefly, the tumour sample, that was frozen at 280uC since
surgical extraction, was thawed and immediately fixed in 1%
formaldehyde for 25 minutes, followed by the addition of 16
glycine solution for 5 minutes, washed in 16PBS twice, frozen in
liquid nitrogen, and finally pulverized mechanically. The following
steps were the same used for breast cancer cell lines.
Statistical Analysis
Data are expressed as mean values of at least three independent
experiments 6 s.d. Student’s t-tests were used to determine
statistically significant differences (*P,0.05).
Results
P-cadherin is co-expressed with C/EBPb and is regulated
by this transcription factor in breast cancer cells
Using a large cohort of invasive breast carcinomas, the
expression of C/EBPb was previously demonstrated to be
significantly associated with P-cadherin expression in about 60%
of the cases [18]; however, the cellular co-expression of these two
proteins was not verified. Thus, based on the hypothesis that C/
EBPb directly activates the CDH3 gene promoter, a double
immunostaining was performed in all invasive breast carcinomas
that previously showed strong positivity for both proteins. As
represented in Figure 1A, C/EBPb expression was found in the
nuclei of the same cells that were expressing P-cadherin at the cell
membrane, pointing for a putative functional relationship between
both proteins.
Based on these results, two different breast cancer cell models
were used to demonstrate if P-cadherin expression could be
affected by C/EBPb: 1) MCF-7/AZ, which is an ER+/luminal
type breast cancer cell line expressing moderate levels of P-
cadherin, and 2) BT-20, an ER-negative/basal-like breast cancer
cell line, highly positive for P-cadherin [17]. The siRNA mediated-
knock-down of C/EBPb induced a significant downregulation of
all C/EBPb isoforms (LAP1, LAP2 and LIP) in both cell lines.
Interestingly, P-cadherin expression was also affected by the
reduction of C/EBPb isoforms, being this effect more pronounced
in MCF-7/AZ cells (Figure 1B). According with these results, and
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in order to decipher which C/EBPb isoform was more relevant for
P-cadherin activation, the expression of LAP1, LAP2 and LIP was
induced in both breast cancer cell lines. As shown in Figure 1C,
only C/EBPb-LIP isoform was able to induce P-cadherin
expression in more than 1.5-fold increase in MCF-7/AZ cells,
while the remaining isoforms did not produce valuable effects on
P-cadherin expression. This result was not found for BT-20 cells,
probably due to their high basal levels of P-cadherin expression
(data not shown).
Interestingly, in a previous study performed by our group, we
found that the CDH3/P-cadherin promoter activation induced by
the LIP isoform was significantly greater compared with the
activation induced by LAP1 and LAP2 [18]. However, in the
present study, this same experiment has been performed and,
although the same significant result was observed at the promoter
level for LIP (p = 0.00079), the CDH3 promoter was also strongly
and significantly activated by LAP1 (p = 0.00002) and less
prominently, but also in a significant way, by LAP2
(p = 0.00032) (Figure 1D). Nevertheless, since it has been described
that LIP can function as a dominant negative inhibitor of both
LAP’s activity [5], we decided to co-transfect both LIP and each
LAP1 or LAP2 , in order to study their combined effect on CDH3
promoter activity. The results showed that there is a significant
increased activation of the promoter with any of the combinations
compared with LAP1 or LAP2 alone, demonstrating that there is
an additive effect of both isoforms (p = 0.00164 and p = 0.00024,
respectively) on CDH3 promoter activation, when added to LIP.
C/EBPb physically interacts with endogenous CDH3 gene
promoter in breast cancer cells
Since the three C/EBPb isoforms were able to transactivate the
1.8 Kb CDH3 promoter gene construct (Figure 1D), we decided to
evaluate in detail the sequence of this putative regulatory region
using distinct bioinformatic tools, which can predict for the
binding of specific transcription factors. Four concordant C/
EBPb-putative binding sites were identified within the first 1400
nucleotides. Interestingly, we found that there is a high degree of
conservation of these predicted C/EBPb binding sites between
humans and other primates within the CDH3 promoter
(Figure 2A), and the left panel of Figure 2B shows their relative
localization.
In fact, in order to demonstrate if there was a physical
interaction between C/EBPb proteins and CDH3 promoter in
these specific binding sites, ChIP has been performed in MCF-7/
AZ breast cancer cells. Indeed, The results showed that there was
an enrichment (relative to input) of the CDH3 DNA-amplified
fragments precipitated with the C/EBPb antibody in all binding
sites (Figure 2B, right panel), demonstrating that C/EBPb
transcription factors directly bind to the selected regions within
the CDH3 promoter.
This same experiment has been performed in BT-20 breast
cancer cells, as well as in a frozen primary basal-like breast
carcinoma, which was selected for being highly positive for P-
cadherin and C/EBPb expression. Interestingly, we could confirm
the results, since there was precipitation with the C/EBPb
antibody in all the binding sites studied, in both cells and primary
tumour (Figure 2C). Moreover, in BT-20 cells, which overexpress
P-cadherin, the binding in all sites was very strong compared with
the one found in MCF-7/AZ breast cancer cells.
C/EBPb binding sites are important for CDH3 gene
activity and are selectively activated by the different C/
EBPb isoforms
In order to evaluate the importance of the aforementioned
binding sites to the CDH3 gene activation, as well as the specificity
of the different C/EBPb isoforms to the CDH3 promoter, point
mutations were introduced in the specific C/EBPb binding
sequences. Figure 3A illustrates the CDH3 point mutations and
their position within the C/EBPb binding sites in relation to the
wild-type CDH3 promoter.
Interestingly, when MCF-7/AZ cells were transfected with the
CDH3 promoter containing point mutations at the binding sites 1
and 4 (CDH3-BS1 and BS4), there was a statistically significant
alteration in CDH3 promoter activity related to the wild-type
promoter sequence (Figure 3B). In contrast, the activity of the
CDH3 promoter was not affected by the mutation introduced at
the BS3 site, and only slightly affected by the introduced mutation
at the binding site 2 (BS2). These results were mostly confirmed in
BT-20 cells, especially for the BS4 mutation, located at the
transcription start site region of the CDH3 promoter, which also
significantly induced its activity (Figure 3B). Although not
significant, the reduction on CDH3 promoter activity observed
with the BS1 mutant was also found in BT-20 cells, suggesting that
this distal C/EBPb binding site is also important to CDH3 gene
transcriptional activation. In addition, the BS2 mutant signifi-
cantly reduced CDH3 promoter activity in BT-20 cells, showing
that this is also a crucial site for the activation of P-cadherin
transcription in this model. Finally, we could not find any effect of
BS3 mutation in CDH3 promoter activity also in BT-20 cells,
proving that this site is not relevant for its regulation.
Since the distinct C/EBPb isoforms have been documented has
having different functions in cancer gene activation and in a cell-
specific context, we co-transfected LAP1, LAP2 and LIP together
with the different mutants of CDH3 promoter in both breast
cancer cell lines. The results demonstrated that distal CDH3-BS1
and BS2 are significantly important for the induced promoter
activity mediated by all C/EBPb isoforms. In contrast, BS3 did
not play a significant role in C/EBPb-mediated CDH3 promoter
activity, since mutations in this specific region were not important
to impair the activation of CDH3 gene mediated by any of the
distinct isoforms. Similar results were observed concerning BS4,
which did not reveal to be important for CDH3 promoter activity
mediated by LAP1, LAP2 or LIP isoforms. Finally, although not
significant, the same trend was observed with BT-20 cells, proving
that BS1 and BS2 are most likely the binding sites where all C/
EBPb isoforms bind to induce P-cadherin transcription in breast
cancer.
Figure 1. Association and regulatory interplay between C/EBPb and CDH3/P-cadherin expression in breast cancer cells. A) Double
immunostaining for C/EBPb and P-cadherin of an invasive breast carcinoma specimen (basal-like carcinoma, histological grade III), where it can be
observed C/EBPb expression in the nuclei and P-cadherin at the cell membrane of tumour cells (magnification6200 and6400-inset); a haematoxylin-
eosin staining of this same case is shown to ascertain tissue integrity (magnification6100); B) Using C/EBPb-targeted siRNA, a consequent reduction
of P-cadherin protein levels was observed in both MCF-7/AZ and BT-20 breast cancer cell lines; C) MCF-7/AZ cells transiently transfected with the
different C/EBPb isoforms (LAP1, LAP2 and LIP) displayed upregulation of P-cadherin protein levels only after induction of the C/EBPb-LIP isoform; D)
Luciferase reporter assays performed in cells transfected with the different C/EBPb isoforms showed that the promoter activation induced by LIP and
LAP1 isoforms was significantly greater compared with the activation induced by LAP2. The co-transfection of both LIP and each LAP1 or LAP2
induced the activation of the CDH3 promoter in an additive manner.
doi:10.1371/journal.pone.0055749.g001
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Discussion
P-cadherin has been receiving a growing interest in the last
years, since its overexpression is significantly associated with high
histological grade breast tumours and with short-term patient
overall survival [11,23–25]. The important association between P-
cadherin expression and well-established markers correlated to
breast cancer poor prognosis, such as high levels of Ki-67,
epidermal growth factor receptor (EGFR), cytokeratin 5 (CK5),
vimentin, p53 and HER2, has been also largely documented [11].
Although P-cadherin has been detected as altered in distinct
tumour models, its effective role in the carcinogenesis process
remains discussible, since it behaves differently depending on the
studied cancer cell context [26]. If in some models P-cadherin has
been suggested to act as an invasion suppressor, such as in
colorectal cancer [27] or in melanoma [28], in several other
models, including breast cancer, P-cadherin behaves as an
Figure 2. C/EBPb physical interaction with the CDH3 gene promoter. A) Putative C/EBPb-binding sites within the CDH3 gene promoter,
where it can be observed their degree of conservation between human and other primates. Grey regions represent total sequence conservation in
comparison with human sequence; B) Proximal regulatory region of CDH3 promoter displaying the relative localization of the predicted C/EBPb
binding sites (left panel). The right panel illustrates the enrichment (relative to input) of the CDH3 promoter DNA-amplified fragments precipitated
from DNA-protein complexes obtained by ChIP in MCF-7/AZ breast cancer cells. C) ChIP experiment performed in BT-20 breast cancer cells and on a
frozen primary breast tumour, highly positive for P-cadherin and C/EBPb expression, also showed the same enrichment pattern for all the putative
binding sites.
doi:10.1371/journal.pone.0055749.g002
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Figure 3. Relevance of C/EBPb-isoforms and their putative binding sites in the activation of the CDH3 gene. A) Schematic
representation of the wild-type and mutated CDH3 promoter; B) CDH3-Luciferase Reporter Assays performed with each of the mutations introduced
at C/EBPb binding sites demonstrating that CDH3-BS1, BS2 and BS4 are the most important for the activity of CDH3 promoter in both MCF-7/AZ and
BT-20 breast cancer cells; *p-value,0.05; C) CDH3-Luciferase Reporter Assays upon co-transfection of LAP1, LAP2 and LIP C/EBPb isoforms, showing
the relevance of specific C/EBPb isoforms across CDH3 promoter binding sites in both MCF-7/AZ and BT-20 breast cancer cells. CDH3-BS1 and BS2, but
not BS3 and BS4, are responsive to all C/EBPb isoforms; *p-value,0.05.
doi:10.1371/journal.pone.0055749.g003
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oncogene, inducing increased tumour cell motility and invasive-
ness when aberrantly overexpressed [12–14,27,29–31].
However, data concerning CDH3 gene regulation in breast
cancer is still very limited. The induction of CDH3 promoter
activity in breast cancer cells was recently described by our group
to be putatively linked to the transcription factor C/EBPb, as well
as P-cadherin and C/EBPb expression have been reported to be
highly associated in human breast carcinomas and linked with a
worse prognosis of breast cancer patients [18]. In fact, the
expression of C/EBPb shares interesting biologic and functional
features with the ones attributed to P-cadherin expression.
Similarly to what has been described concerning C/EBPb biology,
P-cadherin is involved in homeostatic processes, such as cell
differentiation, development and embryogenesis [32]. We have
recently found that P-cadherin enriched cell populations show
enhanced mammosphere forming efficiency (MFE), as well as
increased expression of CD24, CD44 and CD49f, already
described as normal or cancer stem cell markers. These results
allowed to link P-cadherin expression to the luminal progenitor
phenotype of the normal breast hierarchy and established an
indirect effect of P-cadherin in stem cell biology [33]. Interestingly,
these findings come along with observations that C/EBPb
regulates stem cell activity and specifies luminal cell fate in the
mammary gland, categorizing C/EBPb as one of the several
critical transcription factors that specifies mammary stem cells fate
during mammary gland development [34]. In a breast cancer
biology setting, another interesting finding is related to the fact
that P-cadherin, like C/EBPb, is not mutated in breast tumours,
but its overexpression has been widely described in a subset of
aggressive breast cancers [5]. Importantly, at a clinicopathological
level, some C/EBPb isoforms, especially C/EBPb-LIP, correlates
with an ER-negative breast cancer phenotype, highly proliferative
and high grade lesions and poor patient outcome [8,35]. All these
characteristics overlap with the ones observed in highly malignant
breast tumours overexpressing P-cadherin.
The present work demonstrates for the first time that P-
cadherin and C/EBPb co-localize in the same breast cancer cells,
and that there is a physical interaction between this transcription
factor and CDH3 gene promoter. Herein, in addition to the
identification of the promoter binding sites that are relevant for the
transcriptional modulation of CDH3 gene activity by C/EBPb, we
still tested the relevance of the different C/EBPb isoforms along
the CDH3 promoter.
In fact, we show that C/EBPb-LIP is the only isoform capable
to significantly induce P-cadherin protein expression, confirming
in a way the results obtained in our previous study, where a
significant activation of the promoter was only revealed for LIP,
although LAP1 and LAP2 were also able to activate the promoter.
However, in this study, we found that CDH3 gene is also
significantly responsive to LAP1 and slightly to LAP2 isoform at
the promoter level. These significant results were probably due to
improved transfection efficiencies; however, although LAP1 and
LAP2 are activating the gene promoter, supporting the classical
knowledge described for these isoforms as transcriptional activa-
tors, this might not imply that these isoforms induce functional
activity through protein synthesis. In fact, it has been largely
discussed that the functionally transactivation potential of each C/
EBPb isoform can be highly modulated, since this ability strongly
depends not only on dimer composition formed by C/EBPs, but
specially on the partner proteins and responsive elements found in
target gene promoters [5]. The fact that LIP activates CDH3
promoter, leading to protein synthesis, reinforces the emerging
evidence that LIP acts as a transcriptional activator of gene
expression, challenging the long-standing concept that LIP
fashionably functions as a dominant-negative isoform [5]. We
also observed that LAP2 was the C/EBPb isoform that activated
CDH3 promoter in a less extent, which is apparently surprising in
light that LAP2 isoform is considered to be the most transcrip-
tionally active C/EBPb isoform [5]. However, it is also known
that, in transformed cancer cells, an increase in LIP expression
leads to a reduction in LAP2 activity and, therefore, impair its
mediated transcription potential [36].
A novel observation also obtained in this study was the existence
of interaction between C/EBPb proteins to the conserved regions
of the CDH3 gene promoter, identified as C/EBPb responsive
elements. The ChIP results, obtained from the DNA region
containing both BS2 and BS3 binding sites, revealed a cumulative
increased C/EBPb antibody-precipitated DNA when compared to
individual BS1 and BS4, reinforcing the existence of bounding
complexes. This was denoted for both MCF-7/AZ and BT-20
breast cancer cell lines and also for the basal-like tumour studied
by in vivo ChIP.
Concerning the impact of C/EBPb binding sites to the CDH3
promoter activity, we found that BS1, BS2 and BS4 were the most
relevant ones, while BS3 was not responsible for the modulation of
the CDH3 promoter. A detailed analysis of the CDH3 promoter
using the Ensemble ENCODE Project, revealed two DNAse
Hypersensitive (DHS) sites located around BS1 and BS4 specific
sequences, confirming an increased regulatory activity on these
specific regions.
Interestingly, one of the most curious effects was the one found
at BS4, which is located at the transcription start site region of
CDH3 promoter. In contrast with the distal sites, binding
impairment at BS4 significantly induced the activity of CDH3
promoter. In a first approach, we may hypothesize that specific C/
EBPb proteins are regulating negatively the activity of the
promoter through that specific binding site and, upon mutation,
this repression is released. However, since we did not find a
significant effect mediated by LAP1, LAP2 or LIP when BS4 was
mutated, we believe that other factors not C/EBPb-related are
responsible for the negative regulation in this binding site, or the
mutation introduced in BS4 generated a sequence which allowed
the binding of a transcription factor that is able to activate the
CDH3 gene promoter. Additionally, it is also interesting to note
that, although the BS2 mutation did not create a significant
decrease in CDH3 promoter activity in MCF-7/AZ cells, this
binding site is important to LAP2-mediated activation, indicating
that it may not be endogenously active in these breast cancer cells,
but probably highly active in BT-20 cells.
In conclusion, this study contributes to clarify the individual role
of C/EBPb proteins in breast cancer-related CDH3/P-cadherin
gene, as well as to expand the limited characterization of the
mechanisms and players that regulate this pro-invasive protein in
breast cancer.
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Abstract 
P-cadherin is a cell-cell adhesion molecule codified by 
the CDH3 gene, whose expression is highly 
associated with undifferentiated cells in normal adult 
epithelial tissues, as well as with poorly differentiated 
carcinomas. In breast cancer, P-cadherin is frequently 
overexpressed in high-grade tumours, being a well-
established indicator of poor patient prognosis and 
has been reported as an important inducer of cancer 
cell migration and invasion. P-cadherin also confers 
stem cell features to breast tumorigenic cells that 
could be linked to the aggressive behavior of basal-
like breast cancers. P-cadherin has been associated 
with already described stem cell markers, such as 
p63, which was recently demonstrated to 
transcriptionally regulate CDH3 in a context of the 
developmental biology. In fact, the parallelism 
between p63 and P-cadherin interestingly involves the 
cancer and the developmental setting. In cancer, 
however, the relationship between p63 and P-cadherin 
was only explored in a pathological perspective. 
We demonstrate that TAp63 isoforms transcriptionally 
represses CDH3 promoter, downregulating P-cadherin 
protein expression in MCF7/AZ breast cancer cells. 
This repression is functionally reflected on P-
cadherin-induced breast cancer cellular invasion and 
mammosphere-forming efficiency. Interestingly, we 
also observed that this effect of TAp63 isoform on 
CDH3/P-cadherin was not replicated in cells harboring 
p53 mutations, and that the induction of p53 hotspot 
mutations on p53 wild-type cells restored CDH3 
promoter activation. These results suggest that the 
repressive effect of TAP63γ isoform onto CDH3 
promoter is disabled by the p53 mutants. The 
validation of these observations in human breast 
cancer samples revealed that breast tumours 
expressing TAp63γ isoform, but harboring some type 
of known pathogenic p53 mutations were positive for 
P-cadherin expression, while the only case negative 
for P-cadherin expression was the one where no p53 
mutations were detected. Taken together, our data 
reveal previously unknown molecular functions of 
TAp63γ isoform on CDH3/P-cadherin where TAp63γ is 
able to repress CDH3 promoter activity and P-
cadherin expression levels, being this regulation 
dependent of p53 mutational status. 
Keywords: p63 isoforms, CDH3/P-cadherin, p53 
mutations, breast cancer. 
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Introduction 
P-cadherin is a cell-cell adhesion molecule codified by the 
CDH3 gene, whose expression is highly associated with 
undifferentiated cells in normal adult epithelial tissues, as 
well as with poorly differentiated carcinomas. In breast 
cancer, P-cadherin is frequently overexpressed in high-
grade tumours, being a well-established indicator of poor 
patient prognosis and it has been reported as an important 
inducer of cancer cell migration and invasion. P-cadherin 
also confers stem cell features to breast tumorigenic cells 
that could be linked to the aggressive behavior of basal-
like breast cancers. P-cadherin has been associated with 
already described stem cell markers, such as p63, which 
was recently demonstrated to transcriptionally regulate 
CDH3 in a context of the developmental biology. In fact, 
the parallelism between p63 and P-cadherin interestingly 
involves the cancer and the developmental setting. In 
cancer, however, the relationship between p63 and P-
cadherin was only explored in a pathological perspective, 
as their expression is associated between each other and 
with basal-like phenotype in breast cancer [1-5]. 
P63 is distinct from its homologue p53 in that its role as a 
tumour suppressor is controversial, an issue complicated 
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by the existence of two classes of p63 isoforms [6]. In fact, 
P63 expression is driven by two alternative promoters, 
resulting in a full-length TA isoform or an N-terminally 
truncated ΔN form that lacks the transactivation domain. 
Furthermore, ΔNp63 and TAp63 transcripts can be spliced 
to yield α, β, γ, δ or ε variants with alternative C-termini. 
Not only do these isoforms and variants have different 
expression patterns according to cell type and 
differentiation status, they have been reported to possess 
different and sometimes opposing functions, which 
challenges the understanding of p63 function [7]. In 
addition, a recent study has shown that endogenous p63 
proteins binds to thousands of gene promoter target sites 
[8], a fact that, combined with a multiplicity of transcripts 
and protein products of which the literature has perceived 
a wide range of functions (often with conflicting results and 
interpretations), is emblematic of a gene that is among the 
most complex in human physiology [9]. The wide variety of 
targets that are changed in response to p63 include 
transcriptions factors, a large number of adhesion 
molecules, and a functionally diverse set of signaling 
molecules, making p63 a gene that may be directly 
affecting nearly 7% of the coding genes in the genome 
[10].  
P63 is expressed in basal layers of proliferative tissues 
and, similarly to P-cadherin, p63 is expressed in basal 
layers and transiently expressed in various tissues during 
development. P-cadherin and p63 appear to be crucial for 
mammary gland differentiation and, as previously 
described, basal-like breast cancers typically express 
these basal cells markers. Another feature shared 
between P-cadherin and p63 is that their expression is 
associated with undifferentiated and proliferative status of 
these tissues, being crucial for orderly progression of 
terminal differentiation of the epidermis [11-13]. 
Shimomura observed that mutations in the p63 gene, as in 
CDH3/P-cadherin gene, result in hypotrichosis with 
juvenile macular dystrophy (HJMD) and split hand/foot 
malformation (SHFM), and that the expression patterns of 
p63 and P-cadherin overlap in the hair follicle placode and 
apical ectodermal ridge (AER). To clarify this relationship, 
they performed promoter assays and ChIP, which 
revealed that p63 interacts directly with two distinct 
regions of the CDH3 promoter [14]. 
Moreover, in 2006, there was a first work linking p63 and 
regulation of gene expression programs involved in cell 
adhesion, which was published by Carroll and her group 
[15]. A number of genes regulated by TAp63 support the 
notion that p63 is involved in tight transcriptional control of 
epithelial differentiation, cell adhesion, and tumorigenesis 
via cell cycle arrest, apoptosis, and other cellular functions 
[16]. This was recently confirmed by a gene profiling 
microarray supporting TAp63γ as a potent transcriptional 
regulator of gene expression [16].  
The mechanisms controlling CDH3 gene activation has 
only recently start to be explored. The evidences linking 
p63 and P-cadherin, especially connecting them at the 
development and differentiation level, together with the 
transcriptional differences between p63 isoforms, which 
confer to this gene, the ability to induce opposite effects 
on target genes, led us to study whether CDH3/P-cadherin 
was a target of p63 isoforms in breast cancer and 
especially if the transcriptional control over CDH3 was 
differently exerted by the different p63 isoforms. The P-
cadherin induced effects in breast cancer cells was also 
evaluated in the regulatory background exerted by p63 
isoforms.     
Our data reveal previously unknown molecular functions of 
TAp63γ isoforms on CDH3/P-cadherin where TAp63γ is 
able to repress CDH3 promoter activity and P-cadherin 
expression levels, being this regulation dependent of p53 
mutational status. 
 
 
Material and Methods 
Cell Culture and transfections 
Human breast cancer cell lines were obtained as 
described: BT20, MDA-MB-468, MCF10A (ATCC, USA), 
SUM149 (Dr. Stephen Ethier, University of Michigan, 
USA), MCF7/AZ (Prof. Dr. Marc Mareel, Laboratory of 
Experimental Cancerology - Ghent University, Belgium) 
and MCF7/AZ.Mock and MCF7/AZ.Pcad were retrovirally 
stable transduced as described earlier [17]. 
Cells were routinely maintained at 37˚C and 5% CO2, 
MCF10A cells were cultured in DMEM/F12 (1:1), 
supplemented with 5% heat inactivated horse serum 
(Invitrogen Ltd, UK), 10 μg/ml insulin, 0.5 μg/ml 
hydrocortisone, 20 ng/ml EGF, 100 ng/ml cholera toxin 
(Sigma-Aldrich, USA). The other cell lines were grown in 
(Invitrogen Ltd, UK): DMEM (BT20 and MDA-MB-468) and 
DMEM/F12 (1:1) (SUM149 and MCF7/AZ) supplemented 
with 10% heat-inactivated fetal bovine serum (PAA, USA), 
100 IU/ml penicillin and, 100 μg/ml streptomycin 
(Invitrogen Ltd, UK). SUM149 medium was supplemented 
with 5 μg/ml insulin and 1 μg/ml hydrocortisone (Sigma-
Aldrich, USA). 
To perform luciferase reporter gene assays, MCF7/AZ 
cells were growth in 96-well plates to 60% confluence and 
transfection was performed using XtremeGENE 6 
transfection reagent (Roche), according to the 
manufacturer’s instructions. The cells were incubated in 
supplemented medium with the transfectant mix for 24 
hours. 
For all the other techniques, cells were growth in 25 cm
2
 
flasks to 60% confluence and transiently transfected using 
3 μg of cDNA and 9 μL of lipofectamine 2000 (Invitrogen 
Ltd, UK), according to the manufacturer’s instructions. The 
cells were incubated in supplemented medium with the 
transfectant mix for 6 hours. 
 
Promoter and Expression Vectors 
pcDNA3-p63 and pCB6-p53 expression vectors were 
kindly given by Prof. Frank McKeon (Harvard Medical 
School) and by Prof Karen Voudsen (Beatson Institute for 
Cancer Research), respectively. Super-competent E.coli 
cells (TOP10, Invitrogen Ltd, UK) were transformed by 
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heat shock and selected in LB-Agar (AppliChem, GER) 
supplemented with ampicillin. CDH3-luciferase vector was 
generated as described in Albergaria A, 2010 [18]. 
Plasmid DNA was extracted with JETstar 2.0 - Plasmid 
Purification kit (GenoMed, POR), quantified and saved at -
20ºC. 
 
CDH3-Luciferase Reporter Gene Assay  
MCF7/AZ cells were co-transfected with the human full-
length pGL3-CDH3/luc promoter vector and with pCMV-
Renilla luciferase construct (Promega, USA), for 
normalization of transfection efficiency. For promoter 
analysis, 16 hours after transfection, cells were washed 
twice in PBS-cold and then harvested and lysed for 
firefly/Renilla luciferase assays using the Luclite Reporter 
Gene Assay System (Perkin Elmer, UK), according to the 
manufacturer’s instructions. Luciferase bioluminescence 
from Renilla was measured using native coelenteranzine 
substrate reagent (Lux Biotechnology, UK). Individual 
transfection experiments were repeated at least three 
times and in quadruplicate per transfection condition. 
Empty pGL3-basic (E1751) and pGL3-Control (pLUC) 
vectors (E1741), both from Promega, were included as 
controls in all luciferase reporter assays. Luminescence 
was then read using the Wallac/Perkin Elmer-1450-028 
Trilux Microbeta (Perkin Elmer, UK) plate reader, and the 
results are shown as mean of relative light units (RLU). 
 
Western Blotting (WB) 
After transfection and incubation, cells were lysed with 
catenin lysis buffer and concentration of total protein was 
determined by Bradford quantification. The proteins, 
separated in polyacrilamide gel, were transferred to 
nitrocellulose membranes which were incubated for 1 hour 
in milk buffer 5%. The following primary antibodies were 
used: P-cadherin (mouse, clone 56; BD Biosciences, 
USA), p63 (mouse, clone 4A4; Neomarkers, USA) and β-
actin (goat, clone I19; Santa Cruz Biotechnologies, USA). 
All reactions were revealed with luminol and hydrogen 
peroxide, which react with HRP labelled to secondary 
antibodies (Santa Cruz Biotechnologies, USA). Blots were 
exposed to autoradiographic film and quantificatified using 
Quantity One software (Bio-Rad, USA). The experiments 
selected to show are representative ones. 
 
Matrigel Invasion Assay 
Matrigel invasion assay was performed using 8 μm pore 
size BD BioCoat™ Matrigel Invasion Chambers (BD 
Biosiences, USA). In the upper compartment of the 
chamber, 5x10
4
 transfected cells were added, whereas in 
the lower compartment, only fresh supplemented medium 
was present. After 48 hours of incubation at 37°C, the 
upper surface of the filter was cleared from non-invasive 
cells with a cotton swab and washed with PBS. The 
remaining (invasive) cells, which were attached to the 
lower surface of the filter, were fixed with cold methanol 
and stained and mounted with vectashield containing 4,6-
diamidine-2-phenylindolendihydrochrolide (DAPI) (Vector 
Laboratories, Inc., Burlingame, USA). Invasive cells were 
scored by counting the cells in the filter with a 
fluorescence microscope (Leica DM 2000), at 200X of 
magnification. 
 
Mammosphere Formation Efficiency Assay  
Monolayer transfected cells were enzymatically detached 
with trypsin-EDTA (Sigma-Aldrich, USA), manually 
disaggregated with a 25-gauge needle to a single-cell 
suspension and resuspended in cold PBS. Cells were 
plated at 750/cm
2
 in nonadherent culture conditions, in 
wells coated with 1.2% poly(2-
hydroxyethylmethacrylate)/95%ethanol (Sigma-Aldrich, 
USA). Cells were grown for 5 days, in DMEM/F12 
containing B27 supplement, 500 ng/mL hydrochortisone, 
10 μg/mL insulin, 20 ng/mL hEGF and 1% of 
Penicilin/streptomycin. Mammosphere forming efficiency 
(MFE) was calculated as the number of mammospheres 
(≥50 μm) formed, divided by the cell number plated, being 
expressed as a percentage. 
 
BrdU Proliferation Assay 
BrdU incorporation assay was performed to evaluate cell 
proliferation.  Briefly, transfected cells were cultured in 
coverslips, incubated with BrdU for 1 hour and fixed with 
4% paraformaldehyde, for 30 minutes. Cells were first 
treated with HCl 2M for 20 minutes and then incubated 
with anti-BrdU primary antibody (Dako Cytomation, USA) 
for 1 hour, and with anti-mouse FITC secondary antibody, 
for 30 minutes. The samples were mounted with 
vectashield containing DAPI (Vector Laboratories, Inc., 
USA) and the percentage of proliferating cells was 
calculated. 
 
Apoptosis Assay  
TUNEL assay was performed to evaluate apoptosis. After 
transfection, the cell medium was collected and cells were 
enzymatically detached with trypsin-EDTA (Sigma-Aldrich, 
USA). All the cells were added to the initial medium and it 
was centrifuged at 2000 rpm, for 10 minutes, twice. The 
cells were fixed with 4% paraformaldehyde, for 15 
minutes, and another centrifugation was performed (2000 
rpm, 10 minutes). The pellet was re-suspended and each 
sample was added to the wells of the cytospin, and 
centrifuged at 500 rpm, for 5 minutes. The slides were 
incubated for 2 minutes at 4ºC with a permeabilization 
solution (0.1% Triton X-100 in 0.1% Sodium Citrate) and 
with TUNEL-reaction mix (Roche), at 37ºC for 1 hour. 
Finally, cells were washed in the dark and mounted with 
vectashield mounting medium with DAPI (Vector 
Laboratories, Inc., USA). 
 
Tissue Samples 
Eight frozen cases of primary operable invasive breast 
carcinomas were used to assess the RNA expression of 
TAp63 and P-cadherin and also to obtain DNA to analyze 
the p53 mutational status. After selection and isolation of 
the core area of the tumour samples by a trained 
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pathologist, the samples were kept in RNAlater and 
conserved at -80ºC, ensuring an high quality nucleic acids. 
The cases were obtained from the Unit of Genetics and 
Molecular Pathology of the Hospital of Divino Espirito 
Santo, Azores, Portugal, under patient informed consent 
process and with ethical approval by the Hospital Ethical 
Commission. This study was conducted under the national 
regulative law for the usage of human biological 
specimens, where the samples are delinked from their 
donor’s identification and are exclusively available for 
retrospective research purposes.  
 
DNA isolation and p53 mutational analysis 
DNA was isolated using an Invisorb Spin Tissue Mini Kit 
(Invitek), according to the protocol provided by the 
manufacturers. Purity and concentration was determined 
in a ND-1000 spectrometer (Nanodrop). All the samples 
were examined for mutations in all p53 exons covering all 
the coding sequences of the p53 gene. PCR amplifications 
were performed by multiplex according to QIAGEN® 
Multiplex PCR Handbook (Qiagen, Cambridge, MA) and 
using a panel of primers described in the Table S1 
(Supplementary data). 
 
RNA Isolation and RT-PCR  
RNA was isolated using a Qiagen RNAeasy extraction kit 
(Qiagen), according to the protocol provided by the 
manufacturers and concentration was determined in a ND-
1000 spectrometer (Nanodrop). One and half microgram 
of RNA per sample was reverse-transcribed to synthesize 
cDNA, using SuperScript II reverse-transcriptase 
(Invitrogen) according to the manufacturer’s instructions. 
P-cadherin cDNA was amplified using the sense primer 
5'ACGAAGACACAAGAGAGATTGG and the antisense 
primer 5'CGATGATGGAGATGTTCATGG, while TAp63 
cDNA was amplified using the sense primer 
5'AAGATGGTGCGACAAACAAG and the antisense 
primer 5'AGAGAGCATCGAAGGTGGAG. PCRs were 
done using the Qiagen Taq PCR kit (Qiagen) according to 
the manufacturer’s instructions. Reactions were done with 
an initial denaturation at 95ºC for 5 minutes; 30 cycles of 
95ºC for 30 seconds (denaturation), 55ºC (P-cadherin) or 
62ºC (TAp63) for 45 seconds (annealing) and 72ºC for 2 
minutes (elongation); followed by a final extension at 72ºC 
for 10 minutes. Negative controls without cDNA were used 
for all sets of PCRs, as well as, positive controls (one 
breast tumour P-cadherin postitive and a testicule sample 
as TAp63-positive tissue). The products were analysed on 
a 1% agarose gel and compared to a 100-bp DNA ladder 
(Fermentas). 
 
Statistical Analysis 
Data are expressed as mean values of at least three 
independent experiments ± SEM. Student’s t-tests were 
used to determine statistically significant differences 
(*p<0.05; **p<0.01). 
 
 
Results 
TAp63 isoforms transcriptionally represses CDH3 at 
the promoter level and downregulates P-cadherin 
protein expression in MCF7/AZ breast cancer cells. 
The only study showing CDH3 as a transcriptional target 
gene of p63 was published in 2008 by Shimomura and 
colleagues. Although in a context of the developmental 
biology, this work was the first one demonstrating the 
deregulated CDH3 promoter activity mediated by the 
presence of TAp63 isoforms [14]. 
In order to decipher the effect of the different p63 isoforms 
on CDH3 promoter activity in breast cancer cells we co-
transfected MCF7/AZ cells with different p63 isoforms and 
with pGL3-CDH3/luc promoter vector. As shown in Figure 
1A, both TAp63α and γ isoforms are able to reduce the 
basal promoter activation of CDH3. The CDH3-luciferase 
reporter assay also shown that ∆Np63 isoforms 
deregulates CDH3 promoter, although not statistically 
significant and not in a comparable pattern between both
Figure 1. Induction of p63 isoforms differently modulates CDH3/P-cadherin in breast cancer cells. MCF7/AZ cells were 
transfected with isolated isoforms of p63 and CDH3 promoter activity and protein levels where assessed. A. CDH3 luciferase 
gene reporter assays showed that TAp63 isoforms possess a repressive activity in CDH3 promoter, a feature also shared by p63γ. 
Thus, TAp63γ leads to the greater decrease when compared to the endogenous promoter activity (pcDNA3). B. The opposite effects of 
∆Np63 and TAp63 isoforms are even more drastic in protein levels. After 72 hours of transfection with ∆Np63 isoforms, it was observed 
an 1,5-fold increase in P-cadherin levels. In contrast, cells transfected with TAp63 isoforms have a decrease in P-cadherin expression. 
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COOH-terminus α and γ isoforms. Nevertheless, γ isoform 
is also able to induce a considerable reduction on CDH3 
promoter expression. Concerning TA-mediated regulation 
of CDH3 promoter it is interesting to observe that in 
addition to the same effect on transcriptional repression, 
while TAp63α isoform induces a repression of about 40% 
on CDH3 promoter, TAp63γ isoform almost fully 
knockdown it’s basal/control activity within the cells 
(Figure 1A). At the protein level, the opposite effects of 
∆Np63 and TAp63 isoforms on the regulation of P-
cadherin are very clear. While ∆Np63 isoforms induces a 
1,5-fold increase in P-cadherin levels, the general 
transcriptional repressive effects of TAp63 isoforms on P-
cadherin expression is also replicated in accordance with 
the results obtain in luciferase reporter assay (Figure 1B). 
TAp63 counteracts the P-cadherin-induced invasion 
and mammosphere-forming efficiency in breast 
cancer cells.  
It has been largely described the pro-invasive potential 
that overexpression of P-cadherin exerts in MCF-7/AZ 
breast cancer cells [17,19]. More recently, our group also 
demonstrated that P-cadherin mediates stem cell 
properties, namely by conferring increased self-renewal 
ability. In these previous studies we showed that stable 
transduction of P-cadherin in MCF-7/AZ cells (MCF-
7/AZ.Pcad) led to an increase in matrigel invasion capacity 
as well as of mammosphere formation efficiency (MFE) 
when compared with the mock breast cancer cell line. 
These two effects of P-cadherin on invasion potential and 
on MFE in MCF-7/AZ are herein reinforced in Figure 2A 
and 2B. MCF-7/AZ.Pcad cells show a ~4-fold increase 
capacity to invade matrigel (A) when compared with the 
control/empty vector cells (MCF-7/AZ.Mock), an inductive 
effect that is also observed on the mammosphere 
formation efficiency (B).  
The evidence that TAp63γ isoform has the ability to 
heavily repress the transcriptional activity of CDH3 
promoter with consequences on the reduction of the 
expression levels of P-cadherin, led us to study the 
cellular effects mediated by the overexpression of TAp63γ 
in cells stably transfected with P-cadherin (MCF-
7/AZ.Pcad), and therefore, with increased invasion and 
self-renewal potential. Figure 2C show that, similarly with 
what we have observed in MCF-7/AZ cells, in 
MCF7/AZ.Pcad cells, TAp63γ was able to downregulated 
the expression levels of P-cadherin in about 50% 
compared with the cells transfected with empty vector. 
Most importantly, this reduction on the expression levels of 
P-cadherin in P-cadherin-induced cells, is reflected at the 
functional level as we demonstrated that TAp63γ 
counteracts the P-cadherin-induced invasion and 
mammosphere-forming efficiency in breast cancer cells. 
The Figure 2D show that, upon transfection of TAp63γ 
isoform, the invasion rate of MCF-7/AZ.Pcad cells was 
severely reduced in about 70%, when compared with the 
cells transfected with empty vector. A decrease of about 
20% on the mammosphere-forming efficiency was also 
detected on the P-cadherin-induced cells when transiently 
transfected with TAp63γ (Figure 2E). In order to exclude 
that differences observed in the abovementioned 
functional assays were due to apoptosis or altered cell 
proliferation, TUNEL and BrdU proliferation assays were 
performed and no significant differences on apoptosis nor 
in proliferation index were detected in MCF-7/AZ.Pcad 
cells when transfected with TAp63γ (Figured 2F and 2G). 
Figure 2. TAp63γ counteracts the P-cadherin-induced functional properties. A-B. In a breast cancer cell model with induction of P-
cadherin overexpression (MCF-7/AZ.Pcad cells), there is an increase of ~4-fold matrigel invasion capacity (A), as well as, an increase in 
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mammosphere formation efficiency (B) compared with control cells with empty vector (MCF7/AZ.Mock). C-E. Transfection of TAp63γ 
isoform abrogates P-cadherin induced overexpression in MCF-7/AZ.Pcad cells (C), and consequent P-cadherin-induced functional 
properties, such as invasion (D) and mammosphere formation efficiency (E). F-G. TUNEL and BrdU proliferation assay was performed 
to exclude that differences observed in functional assays were due to altered cell proliferation. No significant differences were observed 
in the percentage of cell death (F), neither proliferation (G) when cells were transfected with TAP63γ isoform. 
 
TAp63γ represses CDH3 promoter activity and P-
cadherin expression levels in a p53 dependent 
manner. 
Whole-genome DNA microarrays have identified and 
clustered different breast cancer cell lines in distinct 
molecular subtypes. In this context, the expression of P-
cadherin is heterogeneous across distinct breast cancer 
(BC) cells lines molecular profiles, being however, more 
predominantly presented in basal-like molecular subtype 
cell lines and in normal-like BC cells, such as MCF10A 
cells. Herein, we demonstrated that TAp63γ is able to 
abrogate CDH3/P-cadherin at the transcriptional and 
expression level in a P-cadherin low-expressing MCF-
7/AZ cell line (luminal subtype), as well as in a P-cadherin-
induced cell line, MCF-/AZ.Pcad. In order to test the effect 
exerted by TAp63γ in a panel of P-cadherin-
overexpressing BC cell lines, we transiently transfected 
the TAp63γ isoform in MCF10A, BT20, SUM149 and in 
MDA-MB-468 cells. Interestingly, we observed that the 
repressive effect of TAp63γ isoform over P-cadherin 
expression was not replicated in the basal-like cells. In 
another hand, a moderate reduction of P-cadherin was 
detected in the P-cadherin-overexpressing MCF10A cells 
in the presence of TAp63γ isoform, a result in line with the 
one found in the luminal cells. A feature that has been 
described to be shared among these basal-like cells but 
not in the MCF10A and the luminal breast cancer cell 
lines, MCF7/AZ is the p53 mutation status and, in fact, the 
three basal-like cell lines that we studied herein were 
already described to harbor p53 mutations [20]. Based on 
these findings and on the large amount of evidence 
demonstrating the binding and inhibition of TAp63 activity 
by p53 mutants [21-23], we hypothesized that the 
mutational status of p53 in the basal-like cells interferes 
with TAp63γ, abrogating its repressive effect over P-
cadherin expression. As such, the Figure 3A shows that in 
MCF10A, a p53 wild-type BC cell line [24,25], the 
transfection of TAp63γ leads to a decrease in P-cadherin 
expression, while in mutant-p53 cell lines (BT20, SUM149 
and MDA-MB-468), P-cadherin expression is not affected 
by TAp63γ transfection (Figure 3A). With the purpose of 
testing this hypothesis at the transcriptional level, we used 
MCF7/AZ cells, a cell line displaying a p53 wild-type 
genetic background, which was co-transfected with CDH3-
luciferase reporter and with TAP63γ isoform. Under this 
CDH3 promoter-repressed condition, two different hotspot 
p53 mutations (R175H and R273H) were induced in order 
to evaluate whether these mutations were able to restore 
CDH3 promoter activation. In fact, Figure 3B show that the 
two hotspot p53 mutations, specifically described as 
having a strong effect on the inhibition of TAP63γ 
[7,21,22,26-28], reestablished CDH3 promoter activity, 
demonstrating that the repressive effect of TAP63γ 
isoform onto CDH3 promoter was abrogated by the p53 
mutants.  
In order to validate these observations in human breast 
cancer samples, we analyzed the mutational status of p53 
in a panel of 8 human breast cancer frozen specimens: 4 
samples displaying high levels of TAP63γ RNA expression 
and 4 samples where no RNA expression of TAp63γ was 
detected. We then associate this p53 mutational status 
and TAp63γ RNA expression with P-cadherin RNA levels. 
It is also important to state that P-cadherin RNA 
expression detected on these cases were in accordance 
to previously P-cadherin protein levels detected by 
immunohistochemistry. Figure 3C shows that in breast 
tumours expressing TAp63γ isoform, the only case 
negative for P-cadherin expression was the one where no 
p53 mutations were detected.  By contrast, in all the cases 
displaying some type of known pathogenic p53 mutations, 
the expression of P-cadherin was positive. On the other 
hand, tumour samples negative for TAp63γ, were P-
cadherin positive, irrespectively of the p53 status (Figure 
3C). 
Taken together, these findings led us to conclude that 
TAp63γ is able to represses CDH3 promoter activity and 
P-cadherin expression levels, but this regulation is 
dependent of p53 mutational status (Figure 4). 
 
Discussion 
The shared phenotypes and patterns of expression that 
has been described to P-cadherin and P63 sparked our 
interest in studying the regulatory and functional 
relationship between this potent transcriptional regulator of 
adhesion programme, p63 [15]; and this largely known 
cadherin associated with malignant breast cancer 
phenotype P-cadherin [29-33]. The actual challenge was 
to know the p63 isoform molecular targets and different 
functions since p63 gene generates transcripts encoding 
proteins with or without a N-terminal transactivation 
domain, TAp63 and Np63, respectively. Additionally, 
both transcripts can be alternatively spliced to generate 
proteins with different C-termini , , ,  or  [34]. The aim 
of this work was to characterize the different regulatory 
effects of the different p63 isoforms in CDH3 gene and on 
the expression of P-cadherin and its cellular functions. 
As p63 can come in different flavors, in cancer, it has been 
implicated in tumour formation and progression, acting as 
an oncogene or a tumour suppressor depending on the 
cellular context. 
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Figure 3. TAp63γ represses CDH3/P-cadherin in a p53 dependent manner. A. In wild type-p53 breast cancer cell lines (MCF10A), 
the transfection of TAp63γ leads to a decrease in P-cadherin expression, while in mutant-p53 cell lines (BT20, SUM149 and MDA-MB-
468), P-cadherin expression is not affected by Tap63γ transfection. B. In the p53-wt MCF7/AZ cells, it was observed a recovery of 
CDH3 promoter activity when cells were co-transfected with TAp63γ and with the p53 hotspot mutations, R175H and R273H, compared 
with simple transfection of TAp63γ. C. In breast tumours expressing TAp63γ isoform, the only case displaying no p53 mutations were 
the case also negative for P-cadherin, while all the cases displaying known pathogenic p53 mutations expressed P-cadherin. In the 
other hand, tumour samples negative for TAp63γ, were P-cadherin positive, independently of the p53 status. 
 
Some findings that support p63 as an oncogene are: p63 
is very rarely mutated in cancer [35], but it has been 
shown to be overexpressed in many tumours, especially in 
squamous cell carcinoma of head and neck cancers [36], 
lung [37], cutaneous [38], uterine [39] and breast cancer 
[40,41]. Furthermore, many groups using human 
squamous cell carcinomas demonstrated that these 
tumours actually overexpress the ΔNp63 isoforms [42,43], 
which are the isoforms generally associated with 
oncogenic activity. Convergently, Senoo et al., also 
demonstrated that primary human skin cancers showed a 
loss of TAp63 while normal skin retained its expression 
[43]. In head and neck squamous cell carcinoma 
(HNSCC), although Np63,  and  isoforms are present, 
Np63 is the predominant isoform expressed and is 
overexpressed in tumours compared with matched normal 
tissue specimens, which suggests that Np63 plays an 
anti-differentiation and anti-apoptotic role in the mucosal 
epithelium, possibly playing a key role in the formation of 
HNSCC [44]. Np63 isoforms were also shown to 
inactivate p53 gene, and Rocco et al. suggested that the 
advantage of having ΔNp63 overexpression is the ΔNp63α 
ability to repress the induction of apoptosis. Additionally, it 
was shown that ΔNp63 can act as a dominant negative to 
inhibit p53, TAp63 and TAp73 transactivation and 
consequent apoptosis [45,46]. Moreover, p63 is 
hypothesized to play an important role in maintaining the 
epidermal stem cell population, as well as, in maintaining 
the proliferative capacity of epithelial stem cells [34].  
Nevertheless, all these do not exclude the possibility that 
p63 can also act as tumour-suppressor, as it has been 
suggested by other findings. 
Given the structural similarity between p63 and p53, it has 
been hypothesized that p63 acts as a sensor to DNA 
damage. Indeed, multiple studies have shown that p63 
can induce apoptosis being upregulated in cells that have 
been treated with DNA damaging agents. The most potent 
inducer of apoptosis is the TAp63γ isoform, which 
contains the transactivation domain and lacks the 
inhibitory domain present in the alpha isoforms [47,48]. 
Data not confirmed by our model, in which we do not have 
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variations in TUNEL assay when cells where transfected 
with TAp63γ isoform. 
Many studies were done showing that the knockdown of 
p63 lead to a loss of cell adhesion, cellular arrest, 
invasion, and metastasis, which are important steps in 
tumour progression [15,26,49]. Hu M et al., in 2008, 
suggest that p63 is required for myoepithelial cell 
differentiation and that the elimination of it results in loss of 
myoephithelial cells and progression to invasion [49]. 
Additionally, it has been reported that TAp63α is inhibited 
in metastatic cells, as well as, restoration of TAp63α 
function impairs lamellipodia formation and TGFβ-induced 
migration in vitro and severely opposes metastatic 
dissemination of injected aggressive breast and skin 
cancer cells in immunodeficient mice [26,27]. Taken 
together, these studies indicate that TAp63 bears tumour 
progression and metastasis suppressive properties, ideas 
that fit with our results in which we show a decrease of 
invasion and mammosphere formation efficiency when 
cells were transfected with TAp63γ isoform, a functional 
effect of P-cadherin repression. 
Noticeably, this equilibrium is altered upon p53 mutation, 
the best-understood mechanism by which TAp63 activity 
can be attenuated. Indeed, mutation of p53, one of the 
most frequent lesions in human cancers, does not 
necessarily lead to loss of p53. In contrast, hot-spot 
mutations hitting the p53 DNA-binding domain often cause 
expression of a stable, yet transcriptional deficient mutant-
p53 protein, which is able to form a complex with p63, 
limiting p63 transcriptional activity [26,27]. Although 
molecularly speculative, in our models we observed that in 
wild type-p53 breast cancer cell lines, we have a 
repression of CDH3/P-cadherin by TAp63γ, while in 
mutant-p53 cell lines, P-cadherin expression is not 
affected by Tap63γ transfection, probably by the formation 
of the mut-p53-TAp63 complex, which impairs the TAp63 
activity as transcription factor. This was corroborated by 
the recovery of CDH3 promoter activity when cells are 
transfected both with TAp63γ and mutant-p53, compared 
with cells only transfected with TAp63γ. 
Together, our data demonstrate that TAp63γ represses 
CDH3, limiting P-cadherin induced aggressive behaviour, 
in a p53 dependent manner. 
 
 
Figure 4. Schematic representation of the molecular link 
between P-cadherin, p63 and p53. In wild type-p53 context, 
CDH3/P-cadherin is repressed by TAp63γ. However, in the 
presence of mutant-p53, P-cadherin expression is no longer 
affected by TAp63γ, probably due to the formation of the mut-p53-
TAp63 complexes, which impair TAp63γ to repress its target. 
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Clinically, during cancer progression, the most important processes to determine patient 
prognosis is the presence of cancer cell invasion and metastasis. In an ideal scenario, 
biomarkers should be used to distinguish lesions with high probability to invade and to 
develop clinically relevant metastases from those that will remain indolent. In breast 
cancer, our group has shown that P-cadherin overexpression is a poor prognostic marker 
due to its ability to induce in vitro invasive capacity to cancer cells by the induction of 
MMPs secretion to the extracellular matrix (ECM) (1, 2). These enzymes will degrade the 
ECM, as well as will cleave the extracellular domain of full-length P-cadherin, which 
generates a soluble fragment (sP-cad) with a key role in the induction of cell invasion. 
 
Regarding gene regulation of P-cadherin expression, several signalling pathways and 
cellular mechanisms have been already described has being involved: promoter 
methylation (3), ER-α (1) and BRCA1 expression (4) as P-cadherin repressors; and, on 
the other hand, β-catenin (5), C/EBPβ (6) and p63 (7) as putative activators. 
Nevertheless, the molecular mechanisms underlying P-cadherin de novo expression in 
breast cancer are still far from being well recognized. 
 
The work presented throughout this thesis addressed the validation of two putative 
transcriptional factors, C/EBP and p63, in the regulation of P-cadherin expression in 
breast cancer cells. 
 
C/EBP is one out of six members of a family of leucine zipper transcription factors 
(C/EBPs, CCAAT/enhancer-binding proteins), which have important roles in cellular 
proliferation, differentiation, survival, apoptosis, metabolism, inflammation, transformation, 
and oncogene-induced senescence and tumorigenesis (8). As well as P-cadherin, 
C/EBP is not mutated in breast tumours, but its overexpression strongly associates with 
aggressive behaviour neoplastic features, such as ER-negative tumours, with poorly 
differentiated phenotype, high proliferation rates, basal-like phenotype and worse 
prognosis of breast cancer patients (6, 9). Importantly, C/EBP was also significantly 
associated with P-cadherin expression in breast carcinomas, with nearly 60% of co-
expression of both proteins (6). This association was corroborated in the present work by 
the co-expression of both proteins in the same cells, with the presence of C/EBP in the 
nuclei and P-cadherin at the cellular membrane (Chapter III). Additionally, it is known that 
aberrant expression of C/EBP can lead to cancer progression and multidrug resistance; 
however, the real role of each individual isoform remains to be determined (8). The larger 
C/EBP proteins, LAP 1 and 2 (liver-enriched transcriptional activating proteins), support 
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proliferation and repress differentiation of many cell types (10). On the other hand, the 
smaller protein product, LIP (liver-enriched transcriptional inhibitory protein), lacks the 
transactivation domain and, thus, it was initially believed as acting only as a dominant 
negative repressor (11, 12). However, it is interesting that in some cellular contexts, 
evidences emerged to support a role for LIP as a transcriptional activator of gene 
expression (8). In fact, in the present study (Chapter III), we showed that C/EBP-LIP 
leads to the greater increase of CDH3 promoter activity comparing with the others 
isoforms, which fits both with the idea that LIP can actually act as a transcriptional 
activator and that its induced growth cascade may play a role in the development of 
breast cancer (12). Moreover, C/EBP-LIP not only acts as a transcriptional activator of 
CDH3, but also has a synergistic effect in the presence of C/EBP-LAP isoforms, 
contradicting the theory that C/EBP-LIP acts as a dominant negative repressor in this 
context. Although the molecular mechanism is unclear, C/EBP-LAP2 was considered the 
most transcriptional active isoform of C/EBP (8), data that is also not confirmed in our 
models. In fact, we demonstrated separate and distinct effects of C/EBP-LAP isoforms, 
but with C/EBP-LAP 1 appearing as a higher activator than LAP2. This controversy 
about LAP1 and LAP2 is extended to normal and neoplastic breast tissue, in which the 
same authors described both isoforms as expressed in non-malignant human mammary 
cells, such as MCF10A cells (13), and in breast tumours (14, 15), while others have 
shown that LAP1 is predominantly expressed in normal mammary cells, whereas LAP2 is 
restricted to dividing cells in both normal and neoplastic mammary epithelial cells (16). 
Moreover, it was shown that the overexpression of LAP2 in MCF10A cells leads to 
epithelial–mesenchymal transition and transformation (17). 
 
Together, our data demonstrate that CDH3/P-cadherin is a direct transcriptional target of 
C/EBP. Furthermore, the results corroborate the idea that there are different roles and 
powers for each C/EBPβ isoform and an already described importance for the LIP:LAP 
ratio in the regulation of gene expression in developmental models, as well as in breast 
tumours (9, 14, 15). Increased LIP:LAP ratio have been associated with oestrogen-
receptor-negative, aneuploid, highly proliferative and poor prognosis breast tumours (9, 
14), as well as to a defective transforming growth factor β (TGF-β)-dependent cytostatic 
response in metastatic breast cancer cells. Interestingly, it has been demonstrated that 
the overexpression of LAP2 allows a decreased LIP:LAP ratio and the TGF-β cytostatic 
response, which significantly reduced the  proliferative activity of metastatic cells. In 
contrast, an increased LIP expression antagonises LAP2 activity and the high LIP:LAP 
ratio favours the inactivation of p15/INK4b by FoxO-Smad complex, repression of c-Myc 
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by an E2F4/5-Smad, and the consequent proliferative behaviour of metastatic breast 
cancer cells (15). Curiously, c-Myc is an important transcriptional repressor of CDH3 
gene, when in a complex with BRCA1 (4), leading to decreased levels of P-cadherin 
mRNA and protein. However, c-Myc has also been described as required for β-catenin-
mediated mammary stem cell amplification and tumorigenesis (18), which suggests that it 
has probably a dual role in CDH3 regulation, being a repressor in complex with BRCA1, 
but a required element in the activation of CDH3 by β-catenin. Additionally, Myc is also an 
ERα target, as well as P-cadherin (1, 6), and there is a significant overlap between ERα-
negative tumours and the expression of Myc-regulated genes associated with the control 
of proliferation (19).  
 
p63, another CDH3 transcription factor, is expressed, as P-cadherin, in basal layers of 
proliferative tissues and transiently expressed in various tissues during development, 
suggesting that both proteins have a crucial role in mammary gland differentiation and, as 
previously described, in basal-like breast cancers, which also express these two basal cell 
markers. Another feature shared between these proteins is the association between their 
expression and the undifferentiated and proliferative status of epithelial tissues, being for 
example crucial for the terminal differentiation of the epidermis (20-22). Indeed, 
Shimomura observed that the expression patterns of p63 and P-cadherin also overlap in 
the hair follicle placode and apical ectodermal ridge (AER) and that mutations in the p63 
and CDH3 genes also result in hypotrichosis with juvenile macular dystrophy (HJMD) and 
split hand/foot malformation (SHFM). To clarify this relationship, they performed promoter 
assays and ChIP, which revealed that p63 interacts directly with two distinct regions of the 
CDH3 promoter (7). Moreover, in 2006, a link between p63 and the regulation of gene 
expression programs involved in cell adhesion was first published by Carroll and her 
group (23). These publications, as well as the shared phenotypes and patterns of 
expression, sparked our interest in the relationship between p63 and P-cadherin; 
however, the actual challenge was to know the role of p63 isoforms, since p63 gene 
generates transcripts encoding proteins with or without the N-terminal transactivation 
domain, TAp63 and Np63, respectively. Additionally, both transcripts can be alternatively 
spliced to generate proteins with different C-termini , , ,  or . (24). Thus, the special 
effort of the second part of this work was to clarify the different effects of the different p63 
isoforms in the regulation of the CDH3 gene. 
Depending on the cellular context, and respective isoform, p63 has been implicated in 
tumour formation and progression, acting as an oncogene or as a tumour suppressor. 
Some findings that support p63 as an oncogene are: p63 is very rarely mutated in cancer 
(25), but it has been shown to be overexpressed in many tumours, especially in 
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squamous cell carcinoma of head and neck cancers (26), lung (27), cutaneous (28), 
uterine (29, 30) and breast cancer (31, 32). Furthermore, ΔNp63 isoforms, which are the 
ones generally associated with oncogenic activity, are actually overexpressed in these 
tumours (33-35). Accordingly, it was also demonstrated that primary human skin cancers 
showed a loss of TAp63, while normal skin retained its expression (35). 
In head and neck squamous cell carcinoma (HNSCC), although Np63,  and  isoforms 
are present, Np63 is the predominant isoform expressed and is overexpressed in 
tumours compared with matched normal tissue specimens, suggesting that it has a role as 
an anti-differentiation and anti-apoptotic isoform in the mucosal epithelium, possibly 
playing a key role in the formation of HNSCC (36). Np63 isoforms were also shown to 
inactivate p53 gene and Rocco et al. suggested that the advantage of having ΔNp63 
overexpression is the ΔNp63α ability to repress the induction of apoptosis by inhibiting the 
ability of p73 to transactivate NOXA and PUMA, known apoptosis inducers. Additionally, it 
was shown that ΔNp63 can act as a dominant negative to inhibit p53, TAp63 and TAp73 
transactivation and consequent apoptosis (37, 38). It is also hypothesized that p63 has an 
important role in maintaining the epidermal stem cell population and their proliferative 
capacity (24). 
Nevertheless, a tumour-suppressor role for p63 cannot be excluded by our results and it 
has actually been suggested by other findings. Multiple studies have shown that p63 can 
induce apoptosis, being upregulated in cells that have been treated with DNA damaging 
agents, a role that has been hinted by the structural similarity between p63 and p53. This, 
it has been hypothesized that p63 could act as a sensor to DNA damage. The most potent 
inducer of apoptosis is the TAp63γ isoform, which contains the transactivation domain and 
lacks the inhibitory domain present in the alpha isoforms (39, 40). However, this data was 
not confirmed by our model (Chapter IV), as we do not observe variations in TUNEL assay 
in cells transfected with TAp63γ isoform. 
Several studies demonstrated that the knockdown of p63 lead to a loss of important 
features in tumour progression, such as loss of cell adhesion, cellular arrest, invasion, and 
metastasis (23, 41, 42). Hu et al., in 2008, suggested that p63 is required for myoepithelial 
cell differentiation, since without its expression, there is a loss of myoephithelial cells and 
progression to invasion ensues (42). Additionally, it has been reported that TAp63α is 
inhibited in metastatic cells, and restoring its function impairs lamellipodia formation and 
TGFβ-induced migration in vitro. In addition, it severely opposes metastatic dissemination 
of injected aggressive breast and skin cancer cells in immunodeficient mice (41, 43). 
Taken together, these studies indicate that TAp63 bears tumour progression and 
metastasis suppressive properties, ideas that fit with our results in which we show a 
CDH3/P-cadherin Regulation 
Ana Rita Nobre 
46 
 
decrease of invasion and mammosphere formation efficiency when cells were transfected 
with TAp63γ isoform, a functional effect of P-cadherin repression (Chapter IV). 
Notably, this equilibrium is altered upon p53 mutation, the best-understood mechanism by 
which TAp63 activity can be attenuated. Indeed, p53 mutations, one of the most frequent 
genetic alterations diagnosed in human cancers, does not necessarily lead to loss of p53 
expression. In contrast, hot-spot mutations hitting the p53 DNA-binding domain often 
cause expression of a stable, yet transcriptional deficient mutant-p53 protein, which is 
able to form a complex with p63, limiting its transcriptional activity, and leading to 
increased invasion, migration and metastasis capacities (41, 43). Although molecularly 
speculative, we have observed that in wild type-p53 breast cancer cell lines there is a 
repression of CDH3/P-cadherin by TAp63γ, while in mutant-p53 cell lines, P-cadherin 
expression is not affected by TAp63γ transfection, probably by the formation of the mut-
p53-TAp63 complex, which impairs the TAp63 activity as a transcription factor. This result 
was corroborated by the recovery of CDH3 promoter activity when cells were transfected 
both with TAp63γ and mutant-p53, compared with cells only transfected with TAp63γ. 
Together, our data demonstrate that TAp63γ represses the transcription of the CDH3 
gene, limiting P-cadherin induced aggressive behaviour in a p53 dependent manner. 
Finally, there is evidence of additional signalling pathways involving p63, p53 and P-
cadherin. β-catenin, a  critical activator of CDH3 gene and P-cadherin expression, is 
degraded in normal cells due to p53, which facilitates the degradation of ∆Np63 and 
seems to activate GSK3β. In contrast, in cancer, mutant p53 fails to downregulate ∆Np63, 
which binds B56α, inhibiting GS3Kβ and decreasing phosphorylation levels of β-catenin, 
leading to induced nuclear accumulation of β-catenin and activation of β-catenin-
dependent transcription of genes (44, 45). In addition, the transcriptional upregulation of 
ΔNp63 proteins is also critical for BRCA1 suppressor function and defects in BRCA1-
ΔNp63 signalling are key events in the pathogenesis of basal-like breast cancer (40), a 
molecular subtype of breast cancer with association with P-cadherin overexpression. 
Actually, in breast carcinomas, it has been shown that P-cadherin expression is strongly 
associated with basal-like tumours, as well as, with the presence of BRCA1 mutations 
(46). 
 
Taken all together, mechanisms by which P-cadherin becomes de novo expressed in 
breast cancer are now clearer. However, many questions remain open because all the 
above mentioned transcriptional factors were already described as being expressed in 
normal epithelial tissues and having a role in development and cell differentiation, which 
led us to pursue P-cadherin in the same context and, possibly, find a role on it. The 
existence of stem cells (SCs) has been demonstrated in various adult tissues including 
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brain, bone marrow and peripheral blood, muscle, skin, breast, lung, kidney, liver, 
pancreas and thyroid gland (47-59). However, genes that contribute to the SC phenotype 
and cell differentiation still need to be elucidated. Nevertheless, gene expression studies 
of niche-resident cells have revealed a number of SC markers and regulators of epidermal 
SC maintenance, differentiation and lineage commitment (60), including same regulators 
of CDH3/P-cadherin: C/EBPβ (61), p63 (62), β-catenin (18) and c-Myc (63). Interestingly, 
it has also been proposed that tumours contain rare stem-like cells called cancer stem 
cells (CSC), or tumour initiating cells, characterized by self-renewing capacity, low 
proliferation rates, ability to differentiate into proliferating tumour cells and the ability to 
withstand cancer therapy (64, 65). Serial transplantation of CSCs gave rise to 
heterogeneous tumours with tissue specific cell types of the parental tumour, suggesting 
that only this small subpopulation of neoplastic cells with stem-like capacities promote the 
maintenance and development of the tumour. CSCs have also been suggested as cause 
of tumour reappearance after initially successful treatment, which probably target the bulk 
of neoplastic cells, but do not eradicate CSCs (66). ΔNp63α has been already described 
as an inductor of breast cancer stem cell phenotype, since the overexpression of ΔNp63 
in MCF7 breast cancer cells increased the percentage of the CD44+/CD24- breast CSC 
subpopulation and led to increased cancer cell proliferation, clonogenicity (increased 
colony formation ability in soft agar), anchorage-independent growth (ability to grow into 
mammospheres) and the incidence of tumour xenografts formed in vivo (67). In addition, 
ΔNp63α over-expressing cells were more drug resistant, suggesting that ΔNp63α might 
be a tumour-initiating transcription factor in breast cancer and proposing ΔNp63 as one of 
the possible markers of CSCs in epithelial tissues (67). Furthermore, in normal tissues, 
the functional alterations in ∆Np63 described in both human and mouse models 
underscore the dependence of basal cells of the skin and derived appendages on this 
gene for normal function (68, 69). Moreover, ΔNp63α is selectively expressed at high 
levels in the basal cells of stratified and glandular epithelia and its expression decreases 
with cellular differentiation (39, 70, 71). Presumably, the stem cell compartments exist 
within the basal population (72), thus p63 predominates within a selected subset of 
epithelial tissues, signifying a unique population of stem cells. Supporting this hypothesis, 
Mills et al. observed a complete absence of stratified epidermis in p63-/- mice (68); 
however, Yang et al. observed stratified, but disrupted, epidermis in p63-/- mice (69), 
suggesting that the embryonic epidermis of p63-/- mice undergoes an unusual process of 
non-regenerative differentiation. Thus, p63 is proposed to be critical for the proliferation 
and maintenance of the epithelial progenitor cell populations that give rise to the 
differentiated stratified epithelial cells, rather than for the differentiation process itself. 
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Another player in this controversial issue is p53. Described as “guardian of the genome” 
(73), p53 also takes part in the p53/p63/p73 “orchestra of isoforms to harmonise cell 
differentiation and response to stress” (74). Germline deletion of p53 in mice with critically 
short telomeres spares damaged stem cells from apoptosis and protracts their survival 
(75, 76). Additionally, the skin of such p53-deleted mice displays improved wound healing 
and hair growth, apparently due to increased numbers of epidermal SCs (77); and in a 
mouse model of HER2-overexpressing breast cancer, cultured p53−/− mammospheres 
were found enriched for CSCs due to loss of p53 control over asymmetric cell division 
(78). Similarly, p53-deficient mouse hematopoietic SCs have improved repopulation 
capacity in transplantation assays (79), as well as p53-deficient human hematopoietic 
SCs better resist radiation-induced apoptosis (80). However, and surprisingly, upon 
repeated in vivo expansion without acute genotoxic insult, these cells actually display 
reduced self-renewal capacity, apparently due to persistent accumulation of renewal, by 
maintaining rigorous genome integrity and quality control (80). 
The deletion of p53 also confers an advantage to mutant cells by increasing their 
proliferation rate. By contrast, the absence of c-Myc limits cell propagation. Moreover, 
lower levels of p53 and higher levels of c-Myc make cells highly competitive, with a growth 
or survival advantage (81, 82). Additionally, c-Myc is required for β-catenin-mediated 
mammary stem cell amplification (18), another central player in the epidermal lineage 
selection. Activation of β-catenin signalling pushes cells towards hair follicle differentiation 
(83), while deleting β-catenin in adult stem and progenitor cells directs differentiating cells 
to adopt an interfollicular epidermal fate (84, 85). Although c-Myc is a downstream target 
of β-catenin (86), c-Myc independently influences epidermal cell proliferation, migration 
and lineage commitment (63). Mice with ectopic targeted c-Myc activity in the basal 
undifferentiated epidermis exhibit larger sebaceous glands, hair loss and epidermal 
hyperplasia (87-90). Furthermore, Myc has an essential non-redundant function in the 
maintenance of the self-renewing multipotent stem cell population responsible for the 
regenerative capacity of the mammary epithelium and is required downstream from 
ovarian hormones, for the control of mammary stem and progenitor cell functions (91). 
Also, in a normal breast model, C/EBPβ-deficient mammary epithelial cells showed an 
decreased mammosphere formation efficiency, impaired repopulation ability and 
decreased outgrowth potential, premature mammary epithelial cells senescence and 
increased differentiated luminal cells (61), revealing the importance of C/EBPβ in 
mammary gland development, repopulation activity and luminal cell lineage commitment. 
 
In summary, C/EBPβ, p63, β-catenin and c-Myc pathways are interconnected and usually 
implicated in both cancer and normal stem cells. Additionally, basal layers of normal 
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epithelial tissues, the niche of proliferative and undifferentiated cells, express C/EBPβ, 
p63, β-catenin and c-Myc, as well as, P-cadherin, and during differentiation, these 
markers are lost. Therefore, it is likely that P-cadherin, a marker of poor prognosis in 
breast cancer, inductor of CSC properties and common player in all the above mentioned 
pathways, could also have a role in normal epithelial stem cell maintenance and 
restraining differentiation. 
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CHAPTER VI 
ONGOING AND FUTURE WORK 
CDH3/P-cadherin Regulation 
Ana Rita Nobre 
51 
 
It is now clear that CDH3/P-cadherin’s regulation is a tightly regulated multi-factorial 
mechanism. Therefore, it is mandatory to explore different regulatory mechanisms which 
may be modulating the expression of this protein. Thus, the second aim of this project was 
to disclose new mechanisms that regulate CDH3/P-cadherin expression in invasive 
carcinomas and evaluate if the same mechanisms are also important in the process 
of differentiation of normal epithelial tissues. In order to address this aim, the following 
tasks are being performed: 
 
1. Identification of putative miRNAs underlying P-cadherin de novo expression in 
breast cancer; 
miRNAs are small non-coding RNA molecules recognized as a class of biological 
regulators, acting mainly in a combinatorial regulation mechanism. A given miRNA may 
have multiple different mRNA targets, and a given target might similarly be targeted by 
multiple miRNAs (195, 196). Moreover, different sets of miRNAs are found in different cell 
types and tissues (197), and aberrant expression and dysregulation of miRNAs has been 
already implicated in numerous diseases, including cancer (198-201). Therefore, we 
decided to study if miRNAs could be also responsible for CDH3/P-cadherin regulation, 
since there is no knownledge concerning miRNA profiles in this context. In order to 
achieve this goal, our initial strategy was to perform miRNA microarrays in breast cancer 
models where we could modulate P-cadherin expression levels: BT20 cell line, which 
overexpress P-cadherin, with and without siRNA for CDH3; and MCF7/AZ cell line, 
retrovirally stable transduced to encode P-cadherin (MCF7/AZ.Pcad cell line) (2)). RNA 
extraction was already performed with mirVana - miRNA Isolation Kit (Ambion, USA), 
according to the manufacturer’s instructions, and the differential expression of CDH3/P-
cadherin was confirmed by real-time PCR (Figure VI.1). 
 
 
 
 
 
 
 
 
 
Figure VI.1. Analysis of CDH3 mRNA levels by real-time PCR to validate the P-cadherin modulation in 
our breast cancer cell models. GAPDH mRNA levels were analysed and used as loading control. 
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Subsequently, a DNase treatment (Invitrogen, USA) and an Agilent Human miRNA 
Microarray will be performed, in collaboration with Prof. Manuel Santos from Universidade 
de Aveiro (ongoing work). In the data analysis, a special attention will be given to miRNAs 
targeting the 3’-UTR of P-cadherin and/or its transcription regulators. Additionally, a 
second miRNA profiling will be performed in a small series of P-cadherin positive and 
negative tumours, in order to validate the results. 
At the end of this task, we expect to reveal the specific miRNAs signatures associated 
with P-cadherin expression in breast cancer, as well as the specific miRNAs that suppress 
transcriptional inhibitors of P-cadherin mRNA, allowing the overexpression of this protein 
in this disease. 
 
2. Evaluation of molecular mechanisms regulating CDH3/P-cadherin expression in 
breast cancer and in normal epithelial tissues. 
Although P-cadherin expression and its disturbance are significant during tumourigenesis, 
its expression in normal tissues is “niche-specific” (1, 42). P-cadherin is expressed in 
developing embryos, undifferentiated and proliferative cells in adult epithelial tissues (41), 
and has a critical role, not only to form cell-cell interactions, but also to promote cell 
sorting and cell-signalling events that regulate normal development and differentiation. 
Bearing this in mind, it is also emergent to understand P-cadherin’s regulation in normal 
epithelial tissues.  
In order to evaluate all the described mechanisms of CDH3 regulation in normal epithelial 
tissues, as well as to verify if these are associated with the differential expression of P-
cadherin in the distinct components of these tissues, we are optimizing an in situ 
hybridization of small mRNA molecules assay (202) (Figure VI.2), in collaboration with Dr. 
Ola Soderberg from Uppsala University, Sweden. This methodology will allow us to 
simultaneous genotype transcripts, measure the relative mRNA and evaluate the tissue-
specific transcript variants. All these can be performed directly in both fixed cells and 
tissues, and the signals are amplified with a padlock-rolling circle amplification method 
(202). At the end of this task, we expect to obtain common, as well as distinct, 
mechanisms modulating P-cadherin expression in breast cancer and during differentiation 
of normal epithelia. 
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Figure VI.2. Schematic representation of the in situ 
hybridization of small mRNA molecules 
methodology. cDNA is created using locked nucleic acid 
(LNA)-modified primers and is probed after degradation 
of mRNA by RNase H. RCPs are identified through 
hybridization of fluorescent detection probes. Adapted 
from Larsson et al., 2010 (202). 
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